DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 1 OF 68 6LJQDWXUH3DJH 7KH,QWHUQDWLRQDO'LDEHWHV&ORVHG/RRSL'&/WULDO$ 5DQGRPL]HG&URVVRYHU&RPSDULVRQRI$GDSWLYH0RGHO3UHGLFWLYH&RQWURO03&$UWLILFLDO3DQFUHDV9HUVXV6HQVRU$XJPHQWHG3XPS6$33UHGLFWLYH/RZ*OXFRVH6XVSHQG3/*6LQWKH2XWSDWLHQW6HWWLQJLQ7\SH'LDEHWHV'&/3 Protocol Identifier: DCLP4 IND/IDE Sponsor: Sansum Diabetes Research Institute Version Number: v6.0 14 DEC 2020  JCHR Protocol Director  (name/degree)  John W. Lum, M.S.  Signature/Date    Clinical Lead Investigator  (name/degree)  Jordan E. Pi[INVESTIGATOR_3388], MD  Signature/Date    Engineering Lead Investigator  (name/degree)  Eyal Dassau, PhD  Signature/Date    Medical Monitor  (name/degree)  Roy W. Beck, MD, PhD  Signature/Date    
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 2 OF 68 7KH,QWHUQDWLRQDO'LDEHWHV&ORVHG/RRSL'&/WULDO$ 5DQGRPL]HG&URVVRYHU&RPSDULVRQRI$GDSWLYH0RGHO3UHGLFWLYH&RQWURO03&$UWLILFLDO3DQFUHDV9HUVXV6HQVRU$XJPHQWHG3XPS6$33UHGLFWLYH/RZ*OXFRVH6XVSHQG3/*6LQWKH2XWSDWLHQW6HWWLQJLQ7\SH'LDEHWHV'&/3 Protocol Identifying Number: DCLP4 IND/IDE Sponsor: Sansum Diabetes Research Institute Funded by: [CONTACT_606942]: v6.[ADDRESS_804069] OF ABBREVIATIONS ............................................................................................................................ 9 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_66674] ............................................................ 11 PROTOCOL SUMMARY ............................................................................................................................... 12 SCHEMATIC OF STUDY DESIGN ................................................................................................................ 15 SCHEDULE OF STUDY VISITS AND PROCEDURES ..................................................................................... 16 CHAPTER 1: BACKGROUND INFORMATION ............................................................................................. 17 1.1 Introduction ....................................................................................................................................... 17 1.1.1 Prior Clinical Evaluations of the Proposed AP System ............................................................... 17 1.1.2 Next Generation Artificial Pancreas: Zone MPC and HMS on a Smartphone App ....................................................................................................................................................... 19 1.2 Rationale ............................................................................................................................................ 20 1.3 Automated Insulin Delivery System Description .............................................................................. 21 1.4 Potential Risks and Benefits of the Investigational Device and Study Participation ........................ 22 1.4.1 Known Potential Risks ................................................................................................................ 22 [IP_ADDRESS] Potential Risks and Benefits of the Investigational AID System ........................................ 22 [IP_ADDRESS] Risk of Hypoglycemia ........................................................................................................ 22 [IP_ADDRESS] Risk of Hyperglycemia ....................................................................................................... 23 [IP_ADDRESS] Insulin Infusion Risks ......................................................................................................... 23 [IP_ADDRESS] Venipuncture Risks ............................................................................................................. 23 [IP_ADDRESS] Fingerstick Risks ................................................................................................................. 23 [IP_ADDRESS] Subcutaneous Catheter Risks (CGM) ................................................................................. 23 [IP_ADDRESS] Risks Associated with Device Reuse .................................................................................. 23 [IP_ADDRESS] Questionnaire ...................................................................................................................... 23 [IP_ADDRESS] Other Risks ........................................................................................................................ 24 1.4.2 Known Potential Benefits ............................................................................................................ 24 1.4.3 Risk Assessment .......................................................................................................................... 24 1.5 General Considerations...................................................................................................................... 24 CHAPTER 2: STUDY ENROLLMENT AND SCREENING .............................................................................. 25 2.1 Participant Recruitment and Enrollment ........................................................................................... 25 2.1.1 Pi[INVESTIGATOR_42751] ................................................................................................................................... 25 2.2 Participant Eligibility Criteria ........................................................................................................... 25 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 4 OF 68 2.2.1 Inclusion Criteria ......................................................................................................................... 25 2.2.2 Exclusion Criteria ........................................................................................................................ 26 2.3 Screening Procedures ........................................................................................................................ 27 2.3.1 Data Collection and Testing ........................................................................................................ 27 2.3.2 Screen Failures ............................................................................................................................ 28 CHAPTER 3: PI[INVESTIGATOR_145265] ........................................................................................................................ 29 3.1 Description ........................................................................................................................................ 29 3.2 Enrollment and Screening Procedures ............................................................................................... 29 3.3 Pi[INVESTIGATOR_606925] ..................................................................................................... 29 3.4 Safety Review of Pi[INVESTIGATOR_606926] .................................................................................................... 29 CHAPTER 4: CGM RUN-IN PHASE ............................................................................................................ 31 4.1 Introduction ....................................................................................................................................... 31 4.2 Initiation of CGM .............................................................................................................................. 31 4.3 Assessment of Successful Completion of the CGM Run-in Phase ................................................... 31 CHAPTER 5: RANDOMIZATION VISIT ....................................................................................................... 33 5.1 Visit Timing ....................................................................................................................................... 33 5.2 Data Collection and Testing .............................................................................................................. 33 5.3 Randomization ................................................................................................................................... 33 5.4 Device Training and Study Supplies ................................................................................................. 34 5.4.1 CGM System Training, Initiation, and Supplies ......................................................................... 34 5.4.2 Blood Ketone Meter Training and Supplies ................................................................................ 34 5.4.3 Home Glucagon Emergency Kit ................................................................................................. 34 5.4.4 Study System Training and Device Use ...................................................................................... 34 [IP_ADDRESS] Pump Training .................................................................................................................... 34 [IP_ADDRESS] Study Phone Training ......................................................................................................... 35 [IP_ADDRESS] General Usage Training and System Initiation ................................................................... 36 5.4.5 SAP Training and Device Use ..................................................................................................... 37 CHAPTER 6: CROSSOVER TRIAL HOME PROCEDURES ........................................................................... [ADDRESS_804070] ................................................................................................... 38 6.2 Safety Measures ................................................................................................................................. 38 6.2.1 Drug and Alcohol Use ................................................................................................................. 38 6.2.2 CGM Calibration ......................................................................................................................... 38 6.2.3 Study Pump Failure ..................................................................................................................... 38 6.2.4 Insulin Dosing ............................................................................................................................. 38 6.2.5 Optimization of Insulin Pump Settings ....................................................................................... 38 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 5 OF 68 6.2.6 Hypoglycemia Safety Protocol .................................................................................................... 39 6.2.7 Hyperglycemia Safety Protocol ................................................................................................... 39 6.2.8 Device Data Uploads ................................................................................................................... 39 6.2.9 Remote Monitoring ..................................................................................................................... 39 CHAPTER 7: RCT FOLLOW-UP STUDY VISITS ......................................................................................... [ADDRESS_804071] Schedule during Study Periods 1 and 2 ............................................... 41 7.2 Procedures at Phone Contacts and Follow-up Visits ......................................................................... 41 7.2.1 Phone Contacts ............................................................................................................................ 41 7.2.2 Procedures Performed During Each Follow-up Visit .................................................................. 41 7.2.3 Early Termination Visit ............................................................................................................... 42 7.2.4 Unscheduled Visits ...................................................................................................................... 42 CHAPTER 8: STUDY DEVICES .................................................................................................................... 43 8.1 Description of the Study Devices ...................................................................................................... 43 8.1.1 AID Study System ....................................................................................................................... 43 8.1.2 Insulin Pumps .............................................................................................................................. 43 8.1.3 Continuous Glucose Monitoring ................................................................................................. 43 8.1.4 Blood Glucose Meter and Strips .................................................................................................. 43 8.1.5 Ketone Meter and Strips .............................................................................................................. 43 8.2 Study Device Accountability Procedures .......................................................................................... 43 8.3 Participant Access to Study Device at Study Closure ....................................................................... 43 CHAPTER 9: LABORATORY TESTING AND QUESTIONNAIRES ................................................................. 44 9.1 Laboratory Testing ............................................................................................................................ 44 9.2 Questionnaires ................................................................................................................................... 44 CHAPTER 10: ADVERSE EVENTS, DEVICE ISSUES, AND STOPPI[INVESTIGATOR_16442] ............................................ 46 10.1 Unanticipated Problems ................................................................................................................... 46 10.2 Adverse Events ................................................................................................................................ 46 10.2.1 Definitions ................................................................................................................................. 46 10.2.2 Reportable Adverse Events ....................................................................................................... 47 10.2.3 Hypoglycemic Events ................................................................................................................ 48 10.2.4 Hyperglycemia/Ketosis Events ................................................................................................. 48 10.2.5 Relationship of Adverse Event to Study Device ....................................................................... 49 10.2.6 Severity (Intensity) of Adverse Events ...................................................................................... 49 10.2.7 Expectedness ............................................................................................................................. 49 10.2.8 Coding of Adverse Events ......................................................................................................... 50 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 6 OF 68 10.2.9 Outcome of Adverse Events ...................................................................................................... 50 10.3 Reportable Device Issues ................................................................................................................. 50 10.4 Timing of Event Reporting .............................................................................................................. 51 10.5 Safety Oversight .............................................................................................................................. 51 10.6 Stoppi[INVESTIGATOR_2121].............................................................................................................................. 52 10.6.1 Participant Discontinuation of Study Device ............................................................................ 52 10.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] ................................................................... 53 CHAPTER 11: MISCELLANEOUS CONSIDERATIONS ................................................................................. 54 11.1 Drugs Used as Part of the Protocol .................................................................................................. 54 11.2 Collection of Medical Conditions and Medications ........................................................................ 54 11.3 Prohibited Medications, Treatments, and Procedures ..................................................................... 54 11.4 Rescue Medications ......................................................................................................................... 54 11.5 Pregnancy Reporting ....................................................................................................................... 54 11.6 Participant Compensation ................................................................................................................ 54 11.7 Participant Withdrawal .................................................................................................................... 55 11.8 Confidentiality ................................................................................................................................. 55 CHAPTER 12: STATISTICAL CONSIDERATIONS ........................................................................................ 56 12.1 Statistical and Analytical Plans ....................................................................................................... 56 12.2 Statistical Hypotheses ...................................................................................................................... 56 12.3 Sample Size ..................................................................................................................................... 56 12.4 Outcome Measures .......................................................................................................................... 56 12.4.1 Primary Efficacy Endpoint ........................................................................................................ 56 12.4.2 Secondary Efficacy Endpoints .................................................................................................. 56 [IP_ADDRESS] Secondary Efficacy Endpoint Included in Hierarchical Analysis ..................................... 56 [IP_ADDRESS] Other Secondary Efficacy Endpoints ................................................................................ 57 12.4.3 CGM Metrics Calculations ........................................................................................................ 58 12.5 Analysis Datasets and Sensitivity Analyses .................................................................................... 58 12.5.1 Per Protocol Analyses................................................................................................................ 58 12.5.2 Sensitivity Analyses .................................................................................................................. 59 [IP_ADDRESS] Missing Data ..................................................................................................................... 59 [IP_ADDRESS] Carry-over Effect .............................................................................................................. 59 12.6 Analysis of the Primary Efficacy Endpoint ..................................................................................... 59 12.7 Analysis of the Secondary Endpoints .............................................................................................. 59 12.7.1 Hierarchical Analyses ................................................................................................................ 59 12.7.2 Other Endpoint Analyses ........................................................................................................... 60 12.8 Safety Analyses ............................................................................................................................... 60 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 7 OF 68 12.9 Intervention Adherence and Adaptation .......................................................................................... 61 12.10 Adherence and Retention Analyses ............................................................................................... 61 12.11 Baseline Descriptive Statistics ....................................................................................................... 61 12.12 Device Issues ................................................................................................................................. 61 12.13 Planned Interim Analyses .............................................................................................................. 62 12.14 Subgroup Analyses ........................................................................................................................ 62 12.15 Multiple Comparison/Multiplicity ................................................................................................. 62 CHAPTER 13: DATA COLLECTION AND MONITORING ............................................................................ 63 13.1 Case Report Forms and Device Data ............................................................................................... 63 13.2 Study Records Retention ................................................................................................................. 63 13.3 Quality Assurance and Monitoring .................................................................................................. 63 13.4 Protocol Deviations ......................................................................................................................... 64 CHAPTER 14: ETHICS/PROTECTION OF HUMAN PARTICIPANTS ............................................................ [ADDRESS_804072] (IRB) (or Ethics Committee (EC)) ...................................................... 65 14.3 Informed Consent Process ............................................................................................................... 65 14.3.1 Consent Procedures and Documentation ................................................................................... 65 14.3.2 Participant and Data Confidentiality ......................................................................................... 65 CHAPTER 15: REFERENCES ....................................................................................................................... 67    
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 8 OF 68 Key Roles  Protocol Chairs/Co -Directors  Name, degree  Eyal Dassau, PhD  Title  Director, Biomedical Systems Engineering Research Group  Institution Name  [CONTACT_606956] A. Paulson School of Engineering and Applied Sciences  Name, degree  Jordan E. Pi[INVESTIGATOR_3388] , MD  Title  Research Physician  Institution Name  [CONTACT_606957], degree  John Lum, M.S.  Title  Director, Artificial Pancreas Coordinating Center  Institution Name  [CONTACT_606958], degree  Roy Beck, M.D., Ph.D.  Title  Executive Director  Institution Name  [CONTACT_606959]4 PROTOCOL V6.[ADDRESS_804073]  AID Automated Insulin Delivery  AE Adverse Event  AHCL  Advanced Hybrid Closed -Loop  AP Artificial Pancreas  ATTD  Advanced Technologies & Treatments for Diabetes  AUC  Area Under the Curve  BG Blood Glucose  BGM  Blood Glucose Meter  BMI  Body Mass Index  CFR  Code of Federal Regulations  CRF  Case Report Form  CGM  Continuous Glucose Monitoring  CI Confidence Interval  CLC  Closed -Loop Control  CSII  Continuous Subcutaneous Insulin Infusion  DKA  Diabetic Ketoacidosis  DSMB  Data and Safety Monitoring Board  EC Ethics Committee  FDA  Food and Drug Administration  FDR  False Discovery Rate  FWER  Familywise Error Rate  GCP  Good Clinical Practice  HbA1c  Hemoglobin A1c  HCL  Hybrid Closed Loop  HMS  Health Monitoring System  iAPS  Interoperable Artificial Pancreas System  ID Identification  IDE Investigational Device Exemption  IOB Insulin -on-Board  IQR Interquartile Range  JCHR  Jaeb Center for Health Research  IRB Institutional Review Board  MPC  Model Predictive Control  NIH National Institutes of Health  
 
DCLP4 PROTOCOL V6.[ADDRESS_804074]  Randomized Controlled/Clinical Trial  RBM  Risk-Based Monitoring  SADE  Serious Adverse Device Event  SAE  Serious Adverse Event  SAP Sensor -Augmented Pump  SD Standard Deviation  SH Severe Hypoglycemia  SMBG  Self-Monitoring of Blood Glucose  SUS System Usability Scale Survey  T1D Type [ADDRESS_804075]  UI User Interface   
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 11 OF 68 Site Principal Investigator [INVESTIGATOR_606927]: The International Diabetes Closed Loop (iDCL) trial: A Randomized Crossover Comparison of Adaptive Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) in the Outpatient Setting in Type 1 Diabetes (DCLP4) Protocol Version/Date: v6.0/[ADDRESS_804076] read the protocol specified above. In my formal capacity as a Site Principal Investigator, my duties include ensuring the safety of the study participants enrolled under my supervision and providing the Jaeb Center for Health Research, which serves as the Coordinating Center for the protocol, with complete and timely information, as outlined in the protocol. It is understood that all information pertaining to the study will be held strictly confidential and that this confidentiality requirement applies to all study staff at this site. This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as required by [CONTACT_716] (use applicable regulations depending on study location and sponsor requirements; examples follow): [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812). As the Principal Investigator, I will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary to eliminate an immediate hazard(s) to the trial participants. All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training. Further, I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments. ,QYHVWLJDWRUÂ¶V6LJQDWXUHBBBBBBBBBBBBBBB___________________ Date: _____ / _____ / _____  dd mon yyyy ,QYHVWLJDWRUÂ¶V1DPHBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB Site Name/Number: _____________________________________  
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 12 OF 68 Protocol Summary  Title  The International Diabetes Closed Loop ( iDCL) trial: A Randomized Crossover Comparison of Adaptive 
Model Predictive Control (MPC) Artificial Pancreas Versus Sensor Augmented Pump (SAP)/Predictive 
Low Glucose Suspend (PLGS) in the Outpatient Setting in Type 1 Diabetes (DCLP4)  PrÃ©cis  A randomized  crossover trial will compare the efficacy and safety of an automated insulin delivery (AID) 
study system using an adaptive Model Predictive Control (MPC) algorithm versus SAP (which may or 
may not include PLGS; to be referred to as SAP) therapy in people with type [ADDRESS_804077] 5  participants using the study system for 10 -14 days will be conducted prior to the 
crossover trial.  Investigational 
Device  The AID study system is composed  of a Tandem t:AP pump, a Dexcom G6 continuous glucose 
monitoring sensor, and a smart phone that contains the adaptive algorithm and communicates with the 
other devices.  Objectives  To compare the efficacy and safety of an AID system using an adaptive MPC algorithm versus SAP or 
PLGS therapy in people with type 1 diabetes.  Study Design  Randomized Crossover Trial with two 13 -week periods, preceded by a CGM run -in phase.  Number of 
Sites  5-7 U.S. sites  Major 
Endpoints  Superiority for time in range 70 -180 mg/dL and non -inferiority for time <54 mg/dL measured with CGM 
will be considered primary endpoints, analyzed using a hierarchical gatekeepi[INVESTIGATOR_606928]1c and the following CGM metrics  
x Mean glucose  
x Time >180 mg/dL  
x Time >250 mg/dL  
x Time <70 mg/dL  
x Time <54 mg/dL (superiority)  
x Coefficient of variation  Population  Inclusion  
x Clinical diagnosis, based on investigator assessment, of type [ADDRESS_804078] 3 months (which may include use of automated features)  
x Familiarity and use of a carboh ydrate ratio for meal boluses  
x $JHÂ•\HDUVROG  
x For females, not currently known to be pregnant  
If female and sexually active, must agree to use a form of contraception to prevent pregnancy 
while a participant in the study. A negative serum or urine pregnancy test will be required for 
all females of child -bearing potential. Participants who become pregnant will be discontinued 
from the study. Also, participants who during the study develop and express the  intention to 
become pregnant within the timesp an of the study will be discontinued.  
x If using a personal CGM, willingness to use a Dexcom G6 CGM and discontinue personal 
CGM  use during the study  
x Willing not to begin use of, or not to continue use of if currently using, a personal AID 
(closed  loop contr ol) system during the study; note if the system offers an open -loop mode or 
can be switched to a PLGS mode that is compatible with the Dexcom G6, the system may be 
used during the study in these modes only  
x Willingness to switch to lispro (Humalog) or aspar t (Novolog) if not using already, and to use 
no other insulin besides lispro (Humalog) or aspart (Novolog) during the study  
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 13 OF 68  x Willingness not to start any new non -insulin glucose -lowering agent during the course of the 
trial, and not to use Afrezza during th e trial  
x Investigator believes that the participant can successfully and safely  operate all study devices 
and is capable of adhering to the protocol  
Exclusion Criteria  
1) Use of Afrezza or any non -insulin glucose -lowering agent other than metformin (including 
GLP -1 agonists, DPP -4 inhibitors, SGLT -2 inhibitors, sulfonylureas) unless participant is 
willing to discontinue during the trial.  
2) Two or more epi[INVESTIGATOR_606929] 
6 months  
3) Two or more epi[INVESTIGATOR_1841] o f severe hypoglycemia with seizure or loss of consciousness in the last 6 
months  
4) Hemophilia or any other bleeding disorder  
5) A medical or other condition that in the opi[INVESTIGATOR_606930] a safety concern 
for the participant or put the study at risk  
a. History of frequent severe hypoglycemia  or history of frequent severe hyperglycemia 
and/or ketosis , without emergency room visit  or hospi[INVESTIGATOR_059], due to poor diabetes 
self-management may be disqualifying per investigator judgment  
6) Participa tion in another pharmaceutical or device trial at the time of enrollment or during the 
study  Sample Size  Up to [ADDRESS_804079] 32 completing the trial  Treatment 
Groups  Random assignment (1:1) to begin period 1 either with the AID study system or with SAP using home 
pump and then cross  over to the other respective treatment in period 2  Participant 
Duration  6-7 months  Protocol 
Overview/  
Synopsis  Screening and Enrollment  
x Informed consent will be signed, and eligibility will be assessed  
x Medical history and physical examination  
x HbA1c measurement using point -of-care device (if not available from prior 3 months ) 
x Urine pregnancy test (if applicable)  
x Baseline q uestion naires completed  
Pi[INVESTIGATOR_606931] 1-2 participant s at each site, using a personal Dexcom G5/[ADDRESS_804080] 11 of the prior 14 days and the investigator believes that a CGM run -in is unnecessary.  The Pi[INVESTIGATOR_606932] (1) test the functionality of all aspects of the study System and (2) t rain the clinical 
staff on the execution of the clinical protocol, including hands -on training with the device prior to 
initiating the RCT Period.  Screening and study system start up procedures will be the same as for the 
Crossover Trial. Participants wil l use the study system for [ADDRESS_804081].  Assuming there are no significan t safety or device issues that 
occur, the Crossover Trial will begin.  
CGM Run -In (2 -4 weeks)  
Eligible participants using a personal Dexcom G5/G6 sensor, with use on at least 11 of the prior 14 days 
may skip the CGM run -in unless the investigator believes t hat there is a need to optimize insulin pump 
settings prior to randomization.  Participants skippi[INVESTIGATOR_606933] -in can go directly to the randomization visit.  
Eligible participants not currently using a personal Dexcom G5/G6 sensor or using a Dexcom G5/G6 
sensor with readings captured on less than 11 out of the prior 14 days will initiate a CGM run -in phase 
with a study Dexcom G6 sensor.   
x Users of a sensor other than Dexcom G5/G6 (eg, Medtronic, Abbott) must be willing to 
discontinue use of that sensor for th e duration of the study and users of an AID (closed loop 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 14 OF 68  control) system must be willing to discontinue its use during the study (PLGS mode can be used 
during the study if feasible).  
Duration of the run -in will be [ADDRESS_804082] another opportunity to achieve the 11 day use criterion.  
Randomized Cross -Over Trial  
Eligible participants will be randomly assigned to one of two treatment groups for 13 weeks each:  
1. Group A: study system for period 1 for 13 weeks, then SAP for period 2 for 13 weeks  
2. Group B: SAP for period 1 for 13 weeks, then study system for Period 2 for 13 weeks  
Study System Period:  The participant will be trained regarding AID study system use including meal 
announcement, meal bolusing, correction doses, and exercise. Participants will be expected to use the 
study system at all times at home with the exception of times of illness.   
SAP Period:   During the SAP period, participants will use their own insulin pump and a study -provided 
Dexcom G6 sensor.   
x PLGS mode on the pump can be used if feasible but an AID system cannot be used.  
Study Flow  
Period [ADDRESS_804083] will be performed in applicable subjects, and quality of life and treatment satisfaction 
questionnaires will be completed.  
At the end of per iod 1 visit, the intervention will be switched to the study system or SAP for period 2.  
There will not be a washout period.  
Throughout the study, the occurrence of adverse events and device issues will be solicited and recorded.   
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 15 OF 68 Schematic of Study Design 
 Figure 1. Schematic of Study Design; note clinic visits at 2, 6, and 13 weeks may be replaced by [CONTACT_606943], as detailed in Chapter 7:. 

 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 16 OF 68 Schedule of Study Visits and Procedures Table 1. Schedule of Visits and Procedures During the Crossover Trial 
1. Two 13-Week treatment periods with no intervening washout 2. Will coincide with Randomization Visit for study period 1 3. For study period 2 only 4. For Group B participants (those assigned to use SAP during period 1) only   Screening 
Visit  CGM  
Run-in Visit  Randomization 
Visit  Days (d) or Weeks (w) from the Start of 
Each of Two 13 -Week Study Periods1  0d2 3d 2w 4w 6w 9w 13w Visit (V) or Contact (C)    V V C V C V C V Informed Consent  X          Eligibility Assessment  X          Medical history/  
physical exam  X          Height, weight, 
blood  pressure  and pulse  X         X HbAlc (POC or local lab, if 
needed)  X          HbA1c (Central lab)     X       X C-peptide and 
blood  glucose  (Central Lab)    X        Pregnancy test  (females 
of child -bearing potential)  X  X X3       Questionnaires  X         X Assessment of CGM use  X X         Study system training    X X4       AE Assessment   X X  X X X X X X Upload device data 
from  home      X  X  X  Download  device data 
at clinic visit  X    X  X  X 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 17 OF 68 Chapter 1: Background Information 1 1.1 Introduction 2 Type 1 diabetes (T1D) causes autoimmune pancreatic beta cell destruction and lifelong [ADDRESS_804084] feared and dangerous events 7 for patients and their parents or caregivers (1). Therefore, the ultimate goal in diabetes care is to [ADDRESS_804085] 9 decade, the use of insulin pumps and sensors and their combination (sensor-augmented pumps) [ADDRESS_804086] shown advances towards improving glucose control (2-4). However, recent data from 11 diabetes centers in Europe and the [LOCATION_002] (US) indicate that the glycemic control achieved 12 is still not satisfactory and is complicated by [CONTACT_606944] (5,6), despi[INVESTIGATOR_201020] 13 the advanced technological tools now available (7). Some progress is being made with the 14 introduction of the threshold suspend or predictive low-glucose suspend (PLGS) sensor and 15 pump systems in the [LOCATION_002]. We now need to combine predictive features with PLGS 16 features to minimize hyperglycemia as well (8), without causing anxiety and burden for patients 17 and caregivers due to the demand for continual attention to how well the systems cover meals, 18 snacks and periods of illness. This is especially true in adolescents and some young adults whose 19 compliance with treatment can be low, with 50% omitting or delaying insulin boluses needed for 20 meals (9). Automated decision support systems, and ultimately, full automated management 21 solutions, are strongly desired by [CONTACT_23270] T1D and their caregivers to improve metabolic 22 control and relieve them of the stress and burden of daily treatment of this chronic disease. 23 1.1.1 Prior Clinical Evaluations of the Proposed AP System 24 Several clinical studies using the novel zone MPC control framework which is the basis for the 25 proposed research shows consistently that the Artificial Pancreas (AP) is able to improve glucose 26 regulation in T1D. Dassau et al. (FDA IDE G090129) published in 2013 results of a pi[INVESTIGATOR_606934] 27 trial conducted at Sansum Diabetes Research Institute (SDRI), evaluating individualized, fully 28 automated (no premeal bolus) AP using commercial devices (1). Two trials (n= 22, n=17) were [ADDRESS_804087] algorithm. 30 Continuous glucose monitor (CGM) glucose was maintained in the near-normal range 70-180 31 mg/dL for an average of 70% of the trial time. These results showed the ability of a control 32 algorithm tailored to an individual's physiology to successfully regulate glycemia, even when 33 faced with unannounced meals or initial hyperglycemia. We (FDA IDE G110093) studied the 34 safety and efficacy of a fully automated AP using zone MPC with the health monitoring system 35 (HMS) during unannounced meals and overnight and exercise periods. A fully automated closed-36 loop AP was evaluated in 12 subjects with T1D and demonstrated 80% and 92% time in the 70Â±37 180 mg/dL range for the entire session and overnight, respectively. These results showed that the 38 combination of the zone MPC controller and the HMS hypoglycemia prevention algorithm was 39 able to safely regulate glucose in a tight range with no adverse events despi[INVESTIGATOR_606935] 40 unannounced meals and moderate exercise. The zone MPC algorithm was successfully used in 41 2015 (FDA IDE G130147), when Drs. Dassau and Doyle AP team, Mayo Clinic and SDRI, 42 among other sites, showed in a randomized clinical trial of 32 subjects in a transitional 43 environment (such as hotel) that algorithmic adjustment of individualized insulin dosing 44 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 18 OF 68 parameters was safe and effective for AP use (2). As part of the DP3DK094331 research project, 45 the fruitful collaboration among Drs. Dassau and Doyle AP team, UVA, Mayo Clinic, SDRI and 46 other collaborators yielded a large outpatient clinical trial of the zone MPC and HMS system 47 (FDA IDE G150063), where 30 adult subjects each used AP at home for three months (3). This 48 VWXG\UHVXOWHGLQDVWDWLVWLFDOO\VLJQLILFDQWGHFUHDVHLQ+E$FÃ­&,Ã­WRÃ­49 SDQGK\SRJO\FHPLDGXULQJWKHGD\IURPWRÃ­&,Ã­WRÃ­50 p<0.001) over the three months of AP use (Figure 2). 51 
 52 Figure 2. Change in HbA1c compared to percent time hypoglycemia in a three-month outpatient study 53 comparing our zone MPC algorithm to SAP use in patients with T1D (3). Mean HbA1c change and 54 reduction in percent time CGM glucose <70 mg/dL are shown by [CONTACT_212376]. 55 Individual subjects are shown by [CONTACT_212377]. 56 The zone MPC controller has also been used for outpatient studies in adolescents (FDA IDE 57 G150122), with unannounced exercise multiple times per day and large meals. Mean CGM 58 glucose was significantly lower during AP vs. SAP use (150Â±19 vs 173Â±32, P = 0.042) (4). We 59 also recently concluded a randomized-crossover study comparing glycemic control of the zone 60 MPC AP system versus SAP therapy use at home in which insulin infusion set (IIS) and CGM 61 failures were precipi[INVESTIGATOR_212353] 7 and 21 days of use, respectively, in which results were 62 significantly better for zone MPC compared to SAP use (5). Our second generation target MPC 63 AP system (enhanced MPC, or eMPC) (6) with the addition of a trust index that weights future [ADDRESS_804088] glucose predictions (7) was evaluated in 15 adult subjects studied 65 for 48 hours in SDRI, and achieved 88% time in the target glucose range 70-180 mg/dL (8). 66 

 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 19 OF 68 1.1.2 Next Generation Artificial Pancreas: Zone MPC and HMS on a Smartphone App 67 The zone MPC algorithm has been implemented on the interoperable Artificial Pancreas System 68 (iAPS), a novel, user friendly smartphone application and the system was clinically evaluated in 69 a feasibility study (FDA IDE G180011), where it achieved 83% time in glucose range 70-180 70 mg/dL and mean CGM of 136 mg/dL (9). 71 iAPS is a smartphone-based artificial pancreas platform which provides seamless integration 72 with Dexcom G5 and G6 CGM, and two different insulin pumps: Tandem t:slim and Insulet 73 Omnipod. The app is designed to be cross-platform (Android and iOS), can be used concurrently 74 with typi[INVESTIGATOR_212354] a smartphone, and is designed to be interoperable and compatible with 75 leading devices for diabetes management. As the app resides in a smartphone and connects 76 wirelessly to the CGM and the insulin pump, the complete system is very portable and user 77 friendly. 78 In addition to the hardware integration, the iAPS app provides an interface to the algorithms for 79 AP glucose regulation, namely the zone MPC and the HMS, which provides an audio-visual 80 advisory alarm for hypoglycemia. The app has an intuitive user interface (UI) allowing the user [ADDRESS_804089] an insulin bolus for meal/correction and providing ability to log various activities such 82 as exercise (Figure 3). It also provides alarms for system malfunction, e.g. loss of connectivity 83 with devices, including text-PHVVDJHVWRWKHVXEMHFWÂ¶VFDUHSDUWQHUVIRUDODUPHYHQWVVXFKDV84 impending hypoglycemia. A web-based remote monitoring facility complements the app running 85 on the smartphone allowing the clinician to verify salient features of subjectsÂ¶ glycemic health. [ADDRESS_804090] been clinically evaluated in previous clinical studies (17 IDEs) with 89 over 76,000 hours of human use as shown in Table 2. 90 

 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 20 OF 68 Table 2. Summary of use of prior studies with the Artificial Pancreas System (APS) in different hardware 91 configurations, as well as different variants of the Model Predictive Control (MPC) and Health 92 Monitoring System (HMS) algorithms. 93 Study 
Year  IDE #  Components  Platform  Hours of 
Human Use  Location  PubMed Link  2019  G180011/S002  t:slim -Dexcom  
(ZMPC and HMS)  iAPS  >4,000 Hours  
12 Subjects  Outpatient at 
Home  In Progress  2019  G180011/S001  t:slim -Dexcom  
(ZMPC and HMS)  iAPS  >3,500 Hours  
10 Subjects  Outpatient at 
Home  In Progress  2018  G160279/S002  t:slim -Dexcom  
(ZMPC and HMS)  iAPS  800 Hours  
18 Subjects  Supervised 
Outpatient  In Progress  2018  G180011  t:slim/OmniPod -Dexcom  
(ZMPC and HMS)  iAPS  300 Hours  
6 Subjects  Supervised 
Outpatient  30547670  2017  G150063  [COMPANY_002] -Dexcom  
(ZMPC and HMS)  DiAs  >60,000 Hours  
30 Subjects  Outpatient at 
Home  29030383  2017  G150122/S003  [COMPANY_002] -Dexcom  
(ZMPC and HMS)  DiAs  >6,000 Hours  
19 Subjects  Outpatient at 
Home  28584075  2017  G160281  OmniPod -Dexcom  
(PBH algorithm)  pAPS  >50 Hours  
10 Subjects  Supervised 
CRC  29355439  2017  G160281  OmniPod -Dexcom  
(Target eMPC and  HMS)  pAPS  >700 Hours  
15 Subjects  Supervised 
CRC  29958023  2016  G150122  [COMPANY_002] -Dexcom  
(ZMPC and HMS)  DiAs  >700 Hours  
10 Subjects  Supervised 
Hotel  28459617  2016  G160169  OmniPod -Dexcom  
(Target eMPC and  HMS)  pAPS  >1,950 Hours  
54 Subjects  Supervised 
CRC  29431513  2015  G130147  Animas -Dexcom  
(ZMPC and HMS)  pAPS  >1,500 Hours  
32 Subjects  Supervised 
CRC  26204135  2015  G130236  Animas -Dexcom  
(Target MPC/PID - 
HMS)  pAPS  >1,500 Hours  
30 Subjects  Supervised 
CRC  27289127  2013  G110093/S006  Animas -Dexcom  
(ZMPC and HMS)  APS 36 Hours  
4 Subjects  Supervised 
CRC  24351171  2013  G110093/S003  OmniPod -Dexcom  
(ZMPC/HMS, Inhaled 
Insulin)  APS >200 Hours  
9 Subjects  Supervised 
CRC  25901023  2012  G110093  Animas -Dexcom  
(Zone MPC and  HMS)  APS >275 Hours  
12 Subjects  Supervised 
CRC  24471561  2012  G110069  Animas -Dexcom  
(ZMPC and HMS)  APS >250 Hours  
13 Subjects  Supervised 
CRC  24876535  1.2 Rationale 94 We aim to compare the efficacy and safety of an AID system using an adaptive MPC algorithm 95 versus SAP (which may or may not include PLGS; to be referred to as SAP) in people with type 96 1 diabetes. 97 This study builds on the ideas presented in G150063 (3), where adaptation of insulin delivery [ADDRESS_804091] an automated system that gradually 106 and continually optimizes these settings for the patient, as we believe this will aid controller 107 function to improve time-in-range beyond what can be done today. 108 1.3 Automated Insulin Delivery System Description 109 The interoperable Artificial Pancreas System (iAPS) is an artificial pancreas system (as 110 described in MAF-1625, Amendment #10), composed primarily of an insulin pump, a CGM, and [ADDRESS_804092] 112 insulin doses when glucose concentration is, or is predicted to be, outside the specified target 113 range of 90-120 mg/dL. It includes a redundant safety control that will send warnings of 114 impending hypoglycemia and recommend ingesting carbohydrates immediately to prevent 115 hypoglycemia. 116 iAPS is described in MAF-1625, Amendment #10, and for this study will include: [ADDRESS_804093] to the insulin pump and CGM transmitter. 118 Â¡ Google Pi[INVESTIGATOR_8070] 1, 2, [ADDRESS_804094] to the study phone and use the study phone as their personal 120 phone during closed-loop. 121 x Dexcom G6Â® Sensor & Transmitter 122 x An insulin pump consisting of the Tandem t:AP insulin pump (San Diego, CA) 123 (MAF 2032-A003) 124 x The same core control algorithm successfully used in IDE G180011/S002, G180011/S001 125 and G160279/S002 (Zone MPC with HMS). 126 x The same Health Monitoring System (HMS) algorithm used in G180011/S002, 127 G180011/S001 and G160279/S002 which issues safety notifications to the subject and 128 support personnel to prevent impending hypoglycemia. 129 A schematic of the iAPS system is shown in Figure 4. 130 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 22 OF 68  131 Figure 4. Schematic of the supported principal system hardware components of iAPS. For this study, 132 only the Tandem t:AP pump and Dexcom G6 sensor will be used. 133 1.4 Potential Risks and Benefits of the Investigational Device and Study Participation 134 Risks and benefits are detailed below. Loss of confidentiality is a potential risk; however, data 135 are handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are 136 always a risk in participants with type 1 diabetes and participants will be monitored for this. 137 1.4.1 Known Potential Risks 138 [IP_ADDRESS] Potential Risks and Benefits of the Investigational AID System 139 Even though the study system has been tested prior to this study, there is still a risk that parts of 140 the system may not function properly. The following are possible reasons the system may deliver 141 too much insulin or incorrectly stop insulin delivery: 142 x CGM sensor reads higher or lower than the actual glucose level which increases risk for 143 hypoglycemia and hyperglycemia with automated insulin delivery system; 144 x Device malfunctions that could produce a suspension of insulin delivery or over delivery 145 of insulin. 146 [IP_ADDRESS] Risk of Hypoglycemia 147 As with any person having type 1 diabetes and using insulin, there is always a risk of 148 hypoglycemia.  The frequency of hypoglycemia should be no more and possibly less than it 149 would be as part of daily living.  Symptoms of hypoglycemia can include sweating, jitteriness, 150 

 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 23 OF 68 and not feeling well.  Severe hypoglycemia is possible with loss of consciousness or seizures. 151 Recurrent hypoglycemia may reduce hypoglycemia awareness. A CGM functioning poorly and 152 significantly over-reading glucose values could lead to inappropriate insulin delivery. 153 [IP_ADDRESS] Risk of Hyperglycemia 154 Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 155 extended period or if the pump or infusion set is not working properly.  A CGM functioning 156 poorly and significantly under-reading glucose values could lead to inappropriate suspension of 157 insulin delivery. 158 [IP_ADDRESS] Insulin Infusion Risks 159 The pump infusion set is inserted under the skin.  An infection can occur very infrequently, but, 160 if an infection was to occur, oral and/or topi[INVESTIGATOR_27996]. Infusion set failure 161 (clogs, kinks, accidental removal) may occur, leading to hyperglycemia or ketosis. 162 [IP_ADDRESS] Venipuncture Risks 163 Blood draws can cause some common reactions like pain, bruising, or redness at the sampling 164 site.  Less common reactions include bleeding from the sampling site, formation of a small blood 165 clot or swelling of the vein and surrounding tissues, and fainting. 166 [IP_ADDRESS] Fingerstick Risks [ADDRESS_804095] for several 170 weeks.  The risk of local infection is less than 1 in 1000.  This should not be a significant 171 contributor to risks in this study as fingersticks are part of the usual care for people with diabetes. 172 [IP_ADDRESS] Subcutaneous Catheter Risks (CGM) 173 Use of CGM has a low risk for developi[INVESTIGATOR_007] a local skin infection at the site of the sensor needle 174 placement.  There may be bleeding where the catheter is put in and bleeding under the skin 175 causes a bruise (1 in 10 risk). [ADDRESS_804096] a small portion of the sensor under the skin 177 that may cause redness, swelling or pain at the insertion site. 178 [IP_ADDRESS] Risks Associated with Device Reuse 179 In the study, we may reuse CGM receivers after careful cleaning.  The CGM transmitters and 180 sensors will not be reused. 181 In the study, the insulin pump may be reused after careful cleaning. 182 [IP_ADDRESS] Questionnaire [ADDRESS_804097] been uncommon. 188 [IP_ADDRESS] Other Risks 189 Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 190 the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  191 ,IWKHVHUHDFWLRQVRFFXUGLIIHUHQWDGKHVLYHVRUÂ³XQGHU-WDSLQJÂ´VXFKDVZLWK,97HJDGHUP192 etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 193 medication may be required. 194 Data downloaded from the CGM, pump, and the home glucose and ketone meter will be 195 collected for the study as measures of diabetes self-management behaviors.  Some people may be 196 uncomfortable with the researchers' having such detailed information about their daily diabetes [ADDRESS_804098] benefit to the participants who may learn how to better control 202 their diabetes after the study ends and general benefit to others with diabetes. 203 1.4.3 Risk Assessment 204 The investigators believe that the risk of study participation is small over and above the daily 205 risks of type 1 diabetes outside of a study, based on the facts that (1) people with diabetes 206 experience mild hypoglycemia and hyperglycemia frequently as a consequence of the disease 207 and its management, (2) although the study intervention involves periodic automated insulin 208 dosing that may could increase the likelihood of hypoglycemia, and periodic automated 209 attenuation of insulin delivery that may could increase the likelihood of hyperglycemia, it is 210 more likely that the study intervention will decrease both hypoglycemia and hyperglycemia, and 211 (3) mitigations are in place that limit the likelihood of excessive insulin dosing or prolonged [ADDRESS_804099] their origin in the Declaration of Helsinki, with 216 the protocol described herein, and with the standards of Good Clinical Practice (GCP). [ADDRESS_804100] that the AID study 220 system is experimental. Therefore, an investigational device exemption (IDE) from the U.S. 221 Food and Drug Administration (FDA) is required to conduct the study in the US. 222  223 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 25 OF 68 Chapter 2: Study Enrollment and Screening [ADDRESS_804101] 35 starting and 32 participants completing the 226 crossover trial. A maximum of 60 individuals may be enrolled into screening (i.e., sign the 227 informed consent form and initiate screening).  Participants who have signed consent and started [ADDRESS_804102] is the same (approximately 5-7 participants per 234 site); however, certain sites may recruit additional participants if necessary for the study to meet 235 the overall recruitment goal.  The maximum number to be enrolled into screening at a single site 236 will be 15. 237 Potential eligibility may be assessed as part of a routine-care examination. Prior to completing 238 any procedures or collecting any data that are not part of usual care, written informed consent 239 will be obtained. The study protocol will be discussed with the potential study participant by 240 study staff. The potential study participant will be given the Informed Consent Form to read and 241 will be given the opportunity to ask questions. Potential study participants will be encouraged to 242 discuss the study with family members and their personal physicians(s) before deciding whether 243 to participate in the study. 244 As part of the informed consent process, each participant will be asked to sign an authorization 245 for release of personal information. The investigator, or their designee, will review the study-246 specific information that will be collected and to whom that information will be disclosed. After 247 speaking with the participant, questions will be answered about the details regarding 248 authorization. 249 A participant is considered enrolled when the informed consent form, and assent form if 250 applicable, has been signed. 251 2.1.1 Pi[INVESTIGATOR_42751] 252 The Pi[INVESTIGATOR_42751] (details in Chapter 3) will include 1-[ADDRESS_804103] use CSII and a Dexcom G5/G6 sensor for their usual care.  Participants in [ADDRESS_804104] meet all of the following inclusion criteria in order to be eligible to participate 258 in the study: 259 1) Clinical diagnosis, based on investigator assessment, of type [ADDRESS_804105] 1 year 261 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 26 OF 68 2) Using an insulin pump for at least 3 months (which may include use of automated 262 features) 263 3) Familiarity and use of a carbohydrate ratio for meal boluses 264 4) $JHÂ•\HDUVROG 265 5) For females, not currently known to be pregnant [ADDRESS_804106] 268 will be required for all females of child-bearing potential. Participants who become 269 pregnant will be discontinued from the study. Also, participants who during the study 270 develop and express the intention to become pregnant within the timespan of the 271 study will be discontinued. 272 6) If using a personal CGM, willingness to use a Dexcom G6 CGM and discontinue 273 personal CGM use during the study 274 7) Willing not to begin use of, or not to continue use of if currently using, a personal AID 275 (closed loop control) system during the study; note if the system offers an open-loop 276 mode or can be switched to a PLGS mode that is compatible with the Dexcom G6, the 277 system may be used during the study in these modes only 278 8) Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to 279 use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study 280 9) Willingness not to start any new non-insulin glucose-lowering agent during the course of 281 the trial, and not to use Afrezza during the trial 282 10) Investigator believes that the participant can successfully and safely operate all study 283 devices and is capable of adhering to the protocol 284 2.2.2 Exclusion Criteria 285 1) Use of Afrezza or any non-insulin glucose-lowering agent other than metformin 286 (including GLP-1 agonists, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas) unless 287 participant is willing to discontinue during the trial. 288 2) Two or more epi[INVESTIGATOR_606936] [ADDRESS_804107] 6 months  290 3) Two or more epi[INVESTIGATOR_606937] [ADDRESS_804108] 6 months 292 4) Hemophilia or any other bleeding disorder 293 5) A medical or other condition that in the opi[INVESTIGATOR_606930] a safety 294 concern for the participant or put the study at risk 295 a. History of frequent severe hypoglycemia or history of frequent severe 296 hyperglycemia and/or ketosis, without emergency room visit or hospi[INVESTIGATOR_059], 297 due to poor diabetes self-management may be disqualifying per investigator 298 judgment 299 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 27 OF 68 6) Participation in another pharmaceutical or device trial at the time of enrollment or during 300 the study 301 2.3 Screening Procedures 302 After informed consent has been signed, a potential participant will be evaluated for study 303 eligibility through the elicitation of a medical history, performance of a physical examination 304 by [CONTACT_3462], and local laboratory testing if needed to screen for exclusionary medical 305 conditions. 306 Individuals who do not initially meet study eligibility requirements may be rescreened at a later 307 date per investigator discretion. Individuals who do meet eligibility criteria will proceed to the 308 Pi[INVESTIGATOR_42751], CGM Run-In period, or Crossover Trial (as applicable, see below), which will be [ADDRESS_804109] physical exam (including vital signs and height and weight measurements) will be 312 performed by [CONTACT_606945] (e.g. a physician, fellow, nurse 313 practitioner, or a physician assistant). 314 The following procedures will be performed/data collected/eligibility criteria checked and 315 documented: 316 x Inclusion and exclusion criteria assessed 317 x Demographics (socioeconomic status, date of birth, sex, race, and ethnicity) [ADDRESS_804110] information (retained at the site and not entered into study database) 319 x Medical history 320 x Diabetes history 321 x Concomitant medications 322 x Physical examination to include: 323 Â¡ Weight, height 324 Â¡ Vital signs including measurement of blood pressure and pulse [ADDRESS_804111] for all females of child-bearing potential  328 x The following questionnaires will be administered: 329 Â¡ Diabetes Distress Scale 330 Â¡ Glucose Monitoring Satisfaction Survey 331 Â¡ Hypoglycemia Confidence 332 Â¡ Diabetes Technology Attitudes 333 Â¡ INSPI[INVESTIGATOR_66681] [ADDRESS_804112] approximately 1-2 hours. 335 2.3.2 Screen Failures 336 Individuals who do not initially meet study eligibility requirements may be rescreened at a later 337 date per investigator discretion. 338  339 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 29 OF 68 Chapter 3: Pi[INVESTIGATOR_42751] 340 3.1 Description 341 The Pi[INVESTIGATOR_606938] 1-2 participants at each site, using a personal Dexcom G5/6, with [ADDRESS_804113] 11 of the prior 14 days and for whom the investigator believes that a CGM run-in 343 is unnecessary. 344 The Pi[INVESTIGATOR_606939] (1) test the functionality of all aspects of the study system and (2) [ADDRESS_804114] be using a Dexcom G5/[ADDRESS_804115] a phone call 358 3 days (+/- 1 days) after initiation of home use of the study system. Procedures will match those [ADDRESS_804116] a follow up visit at the end of the home use period. Visit procedures will 361 include the following: 362 x Assessment of adverse events, adverse device effects, and device issues 363 x Download of study system and CGM data  364 x Download of blood glucose meter and ketone meter 365 x Return of AID study system components (phone and insulin pump) and switch back to 366 personal insulin pump 367 Â¡ Participants interested in participating in the RCT may at the discretion of the [ADDRESS_804117] been resolved and any associated approvals (IRB, 376 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 30 OF 68 FDA, DSMB) have been obtained.  If repeated, participants could have participated in the earlier [ADDRESS_804118] include: 379 a) No serious adverse events related to use of the iAPS during the pi[INVESTIGATOR_32731]. 380 b) All subjects have demonstrated an independent ability to initiate the iAPS system 381 and operate it safely, as judged by [CONTACT_55794]. 382 c) Investigators and engineering team are able to confirm that adaptation of clinical 383 parameters is running successfully within the predefined bounds. 384  385 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 31 OF 68 Chapter 4: CGM Run-in Phase 386 4.1 Introduction 387 Eligible participants using a personal Dexcom G5/G6 sensor, with use on at least 11 of the prior 388 14 days may skip the CGM run-in unless the investigator believes that a run-in is necessary prior 389 to randomization.  Participants skippi[INVESTIGATOR_606933]-in can go directly to the randomization visit. 390 Eligible participants not currently using a personal Dexcom G5/G6 sensor or using a Dexcom 391 G5/G6 sensor with readings captured on less than 11 out of the previous 14 days will initiate a 392 CGM run-in phase with a Dexcom G6 sensor. 393 x Users of a sensor other than Dexcom G5/G6 (eg, Medtronic, Abbott) must be willing to 394 discontinue use of that sensor for the duration of the study and users of an AID (closed 395 loop control) system must be willing to discontinue its use during the study (PLGS mode 396 can be used during the study if feasible). 397 4.2 Initiation of CGM 398 The participant will be provided with sensors and a transmitter and a blood glucose meter, and 399 instructed to use the study CGM on a daily basis.  Training will be provided to participants not 400 experienced with CGM use as to how to use the CGM in real-time to make management 401 decisions and how to review the data after an upload for retrospective review. Participants using 402 a personal CGM prior to the study will discontinue the personal CGM beginning in this period. 403 x The participant will be given a CGM receiver (if desired) and trained on its use, or will be 404 trained on the installation and use of the Dexcom phone-based mobile app 405 Â¡ Participants may use available Dexcom software and features of the study CGM related [ADDRESS_804119] will be used to document and facilitate the training 409 process. 410 $SK\VLFDORUHOHFWURQLFFRS\RIWKHVWXG\&*0XVHUÂ¶VJXLGHZLOOEHSURYLGHGIRUWKHSDUWLFLSDQW[ADDRESS_804120] the participant with any system use issues and for pump 416 settings optimization.  417 Visit procedures will include the following: [ADDRESS_804121] 11 out 422 of the previous 14 days.  If a participant fails to meet this criterion, or if it is determined that the 423 participant will benefit from additional time with CGM use, the run-in period may be extended at 424 the discretion of the investigator. One additional period may occur, with another clinic visit to 425 assess results after the second period using the same criteria as above. The run-in duration will 426 therefore vary from approximately 2 to 4 weeks, depending on the participant. Additional visits 427 and phone contacts for further training are at investigator discretion. 428 Participants who are unable to meet the CGM compliance requirements will be withdrawn from 429 the study, as will participants who no longer meet all of the inclusion and exclusion criteria. 430  431 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 33 OF 68 Chapter 5: Randomization Visit [ADDRESS_804122] not proceed to randomize an 434 individual until they are convinced that the participant is eligible and will accept assignment to 435 either of the two treatment orders. 436 5.1 Visit Timing 437 The randomization visit is expected to begin on the same day the CGM Run-In period is 438 completed (or it can be on the same day of screening if the run-in phase is skipped).  If not on the 439 same day, the randomization visit should occur within 14 days of the end of the run-in phase (or 440 screening visit if run-in skipped). [ADDRESS_804123] physical exam 447 described in section 2.3 will be repeated. 448 Eligibility criteria from screening will be reviewed again (if not the same day) to verify 449 eligibility, and the study staff will evaluate whether the participant can safely use the study 450 system.  If the participant is no longer eligible based on these criteria, the participant will be 451 dropped from the study. 452 5.2 Data Collection and Testing 453 The following procedures will be done at the randomization visit: 454 x Blood sample to send to the central laboratory for HbA1c; random, non-fasting C-peptide; [ADDRESS_804124] for all females of child-bearing potential (if not performed within the 457 prior 6 days) 458 5.3 Randomization 459 Eligible participants will be randomly assigned, stratified by [CONTACT_3725], to one of two groups to 460 determine treatment order during the 26-week study: 461 1. Group A: study system for period 1 for 13 weeks, then SAP for period 2 for 13 weeks 462 2. Group B: SAP for period [ADDRESS_804125] one will be given a prescription for the glucagon emergency kit. 479 5.4.4 Study System Training and Device Use 480 Participants assigned to Group A will receive study system training prior to initiating period 1 of 481 the crossover trial. These training sessions can occur on the same day as the randomization visit 482 or extend to up to one additional session within the next 7 days if needed; participants will not 483 take the study system home and initiate period 1 until training has been completed. 484 Participants assigned to Group B will receive study system training upon completion of period 1 485 (the SAP period). These participants will have the same option as above of completing training 486 the same day as the period 1 13-Week Visit, or else within a 7-day period following that visit, 487 prior to initiating home use of the study system. 488 Participants will receive study system training by [CONTACT_606946]. The study 489 system includes the Tandem t:AP insulin pump and Dexcom G6 CGM. The system also includes 490 the study phone. 491 [IP_ADDRESS] Pump Training 492 Pump training will include the following: [ADDRESS_804126] and correction 496 boluses. Additional topi[INVESTIGATOR_137345]: infusion site initiation, 497 cartridge/priming procedures, setting up the pump, charging the pump, navigation through [ADDRESS_804127] the participant in study pump infusion site initiation and will 500 start the participant on the study pump. The study pump will be programmed with the 501 SDUWLFLSDQWÂ¶VXVXDOEDVDOUDWHVDQGSXPSSDUDPHWHUV7KHSDUWLFLSDQWÂ¶VSHUVRQDOSXPSZLOO[ADDRESS_804128] will be used to document and facilitate the 508 training process; a physical or electronic copy of the pump user guide will be provided for [ADDRESS_804129] until the 511 subsequent visit. 512 [IP_ADDRESS] Study Phone Training 513 Study phone training will include: 514 x 7KHVWXG\WHDPZLOOFRQILUPWKHVXEMHFWÂ¶VSDUDPHWHUVDUHHQWHUHGLQWKHV\VWHP$3650515 with the study physician. 516 x How to switch the system between Pump mode (open-loop, preprogrammed basal insulin 517 delivery) and Closed Loop mode depending on circumstances.  518 x +RZWRFDOLEUDWHWKH&*0XQLWGXULQJWKHVWXG\DVSHUPDQXIDFWXUHUÂ¶VLQVWUXFWLRQVDQGSHU519 clinical need. 520 x How to access the CGM trace from the sensor on the phone screen. Study staff will also 521 H[SODLQWKHFRQFHSWRIÂ³VDIHEDVDOÂ´WRWKHVXEMHFWVZKLFKFDQEHDFWLYDWHGDIWHU&*0522 connectivity is interrupted to the study phone. 523 x How to activate the meal bolus screen of the phone system any time insulin will be given 524 with a meal or any time additional correction insulin is desired. 525 Â¡ Specifically, study staff will follow inform the subject that: [ADDRESS_804130] the final dose to be delivered, regardless of 533 what settings are entered into the other boxes (glucose value, carbohydrates, 534 correction). The amount shown in this box will be delivered. [ADDRESS_804131] 542 to safety/alert messages. 543 x How to perform blood ketone testing. 544 x Review of the iAPS App User Guide; a physical or electronic copy will be provided for [ADDRESS_804132] to the study phone and 552 use the study phone as their personal phone during closed-loop. Subjects will be assisted by 553 study staff in this setup process. At the end of study system use, the study phone will be factory 554 reset to remove any personal data from the study device. 555 [IP_ADDRESS] General Usage Training and System Initiation 556 The participant will be instructed to use the system in closed-loop mode except 1) when no CGM 557 sensor is available or 2) if insulin is delivered by [CONTACT_3451] (e.g. 558 injection of subcutaneous insulin via syringe in the event of infusion site failure). If insulin is [ADDRESS_804133] study staff during periods of illness with an 562 elevated temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), periods of significant 563 illness, or during periods of use of medications such as epi[INVESTIGATOR_418074] 564 of a severe allergic reaction or asthma attack in addition to use of oral or injectable 565 glucocorticoids to determine if closed-loop use should be temporarily discontinued. 566 Participants will be specifically instructed: 567 1) Not to upgrade the phone operating system or the iAPS app will no longer allow closed-568 loop operation. 569 2) Not to plug headphones into the study phone or alerts will be silenced. 570 3) Not to put the phone on vibrate mode or alerts will be silenced. 571 4) Not to use any manufacturer provided (e.g. Dexcom G6 Mobile App) or third-party 572 components for CGM connectivity and monitoring, as this will interfere with 573 connectivity to the study phone. 574 After study system training has been completed, participants in Group A will proceed with home 575 use of the study system. Participants may use the study pump and study phone without closed-576 loop and study CGM during periods of component disconnections or technical difficulties. 577 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 37 OF 68 5.4.5 SAP Training and Device Use 578 During the SAP period, participants will use their own insulin pump and the study Dexcom G6 579 sensor. If a participant is using a home pump with PLGS capability compatible with the study 580 sensor, he/she may keep the pump in PLGS mode; however, an AID system cannot be used. [ADDRESS_804134]-party 586 components for this purpose. 587  588 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 38 OF 68 Chapter 6: Crossover Trial Home Procedures [ADDRESS_804135] physicians perform data-driven optimizations of 628 pump settings, but instead to try to limit changes to safety concerns only. 629 6.2.6 Hypoglycemia Safety Protocol 630 During the course of the study, participants will be permitted to change the CGM low glucose 631 threshold alert setting on their device or mobile app (as applicable), but will be instructed to 632 choose a value no less than 60 mg/dL. 633 If a participant receives a CGM hypoglycemia threshold or predictive alarm or notes that the 634 CGM glucose is below the hypoglycemia threshold alarm value, confirmatory fingerstick testing 635 will be performed if required by [CONTACT_606947] 636 hypoglycemia with ~[ADDRESS_804136]-acting oral glucose. 637 6.2.7 Hyperglycemia Safety Protocol 638 During the course of the study, participants will be permitted to change the CGM high glucose 639 threshold alert setting on their device or mobile app (as applicable), but will be instructed to 640 choose a value no greater than 300 mg/dL. 641 If a participant receives a CGM hyperglycemia threshold alarm or notes that the CGM glucose 642 is above the hyperglycemia threshold alarm value, confirmatory fingerstick testing will be 643 performed if required by [CONTACT_606948]. 644 ,IDSDUWLFLSDQWÂ¶V&*0UHDGLQJLV!PJG/IRURYHUKRXUVRUÂ•PJG/DWDQ\point, the 645 participant will be instructed to take the following steps: 646 x Perform a blood glucose meter check. 647 x If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter. 648 x If the ketone level is >0.6 mmol/L, take correction insulin, change insulin (pump) infusion [ADDRESS_804137] (if personal SIM card is not 654 being used) to ensure near continuous automatic upload of data to the remote monitoring system. 655 During the SAP study period, participants will be asked to upload CGM data (and pump data, if 656 possible) prior to each scheduled phone call or clinic visit. [ADDRESS_804138] real-time event-based remote monitoring alerts 659 present from the study phone to notify study staff of prolonged periods of hypoglycemia (>30 660 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 40 OF 68 minutes <70 mg/dL) or hyperglycemia (>2 hours above 300 mg/dL, or greater than 400 mg/dL at 661 any time). On-call clinic staff will contact [CONTACT_606949] [ADDRESS_804139] the subjects at any time for concerns arising 675 from remote monitoring data. 676  677 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 41 OF 68 Chapter 7: RCT Follow-up Study Visits [ADDRESS_804140] Schedule during Study Periods 1 and 2 680 During each of the two 13-Week study periods, visits and contacts will be scheduled as outlined 681 in Table 3 below: [ADDRESS_804141] Schedule 683 Target Day/Week  Type  Target/ Allowable Window  
(around Target Day/Week)  3 days*  Phone  +/- 2 days  2 weeks  Visit ** +/- 4 days  4 weeks  Phone  +/- 7 days  6 weeks  Visit ** +/- 7 days  9 weeks  Phone  +/- 7 days  13 weeks  Visit ** +/- 7 days  * During the study system use period, this [ADDRESS_804142] to the start of the period 685 ** Videoconferences may be performed instead of in-person visits at investigator discretion, for example in case of 686 local restrictions on in-clinic visits or participant-specific quarantine/isolation requirements; 13-Week visits 687 involving iAPS system training/initiation must be in-clinic unless formal permission is obtained from clinical [ADDRESS_804143], the participant will be asked to upload device data as described in 693 section 6.2.8 for study staff review.  During the phone call, study staff will: 694 x Assess compliance with study device use 695 x Answer questions about using the study system 696 x Assess adverse events, adverse device effects, and device issues 697 x Review glycemic control 698 Phone contacts may be performed via videoconference at investigator discretion. 699 7.2.2 Procedures Performed During Each Follow-up Visit 700 The following procedures will be done at all visits in both periods, unless otherwise stated 701 x Assessment of compliance with study device use 702 x Retraining on system use as needed 703 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 42 OF 68 x Assessment of adverse events, adverse device effects, and device issues 704 x Download of CGM data (when available), blood glucose meter data, and blood ketone 705 meter data (for videoconferences, participant upload of any devices that supports cloud 706 upload, and subsequent download by [CONTACT_96937]) [ADDRESS_804144] blood glucose meter with the available concentration(s) of 708 control solution if the meter is brought to the visit (except for 13-week visit of period 2) 709 In addition, the following will be done at the 13-week visit in each period, unless otherwise 710 stated: [ADDRESS_804145] for females of child-bearing potential (period 1 only); for [ADDRESS_804146] result 714 x Participant weight, height, and blood pressure and pulse; for videoconferences, a verbal 715 UHSRUWRIWKHSDUWLFLSDQWÂ¶VZHLJKWDQGKHLJKWZLOOEHDFFHSWDEOH 716 x Collection of a blood sample to send to the central laboratory for HbA1c determination; 717 for videoconferences, a capi[INVESTIGATOR_606940] a study-provided 718 kit and mailed to the central laboratory 719 x Completion of the following questionnaires: 720 Â¡ Diabetes Distress Scale 721 Â¡ Glucose Monitoring Satisfaction Survey 722 Â¡ Hypoglycemia Confidence 723 Â¡ Diabetes Technology Attitudes 724 Â¡ INSPI[INVESTIGATOR_66681] (following study system period only) 725 Â¡ System Usability Scale Survey (SUS) (following study system period only) 726 x Return study devices as appropriate 727 x Initiate period 2 devices (end of period 1 only) [ADDRESS_804147] back on pre-study insulin delivery method and glucose monitoring method at 729 13-week visit (end of period 2 only). [ADDRESS_804148] the participant has with the site for 736 significant protocol-related issues/questions outside the visit schedule. 737  738 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 43 OF 68 Chapter 8: Study Devices 739 8.1 Description of the Study Devices 740 8.1.1 AID Study System 741 The study system is composed of a Tandem t:AP pump, a Dexcom G6 continuous glucose 742 monitoring sensor, and a smart phone that contains the adaptive algorithm and communicates 743 with the other devices. 744 8.1.2 Insulin Pumps 745 During the study system period, participants will use a Tandem t:AP pump.  During the SAP [ADDRESS_804149] once every 10 days. Only approved insertion sites will be used (abdomen). 752 8.1.4 Blood Glucose Meter and Strips 753 Blood glucose levels will be measured using the study-assigned blood glucose meter 754 (glucometer) and the CGM device will be calibrated if needed using the study glucometer and 755 VWULSVLQDFFRUGDQFHZLWKWKHPDQXIDFWXUHUÂ¶VODEHOLQJ 756 8.1.5 Ketone Meter and Strips 757 Blood ketone levels will be measured using the Abbott Precision Xtra (or equivalent meter, such 758 as the Optium Neo) meter and strips in accordance with manufacturer labeling. Any blood 759 glucose meter component of ketone meters will not be used. 760 8.2 Study Device Accountability Procedures 761 Device accountability procedures will be detailed in the site procedures manual. 762 8.3 Participant Access to Study Device at Study Closure 763 Participants will be permitted to keep the blood glucometer and blood ketone meter at the end of 764 the study, but will need to return all other devices, including study phone, insulin pump, and 765 CGM components and related supplies. 766  767 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 44 OF 68 Chapter 9: Laboratory Testing and Questionnaires 768 9.1 Laboratory Testing 769 HbA1c: [ADDRESS_804150] 3 months 772 x A blood sample will be obtained for central lab analysis at Randomization and at the 773 conclusion of each 13-Week Crossover Trial period. Final HbA1c also may be collected 774 from participants who withdraw from the study. 775 Random C-Peptide and Glucose: 776 x Collected at Randomization for central lab analysis  777 Urine Pregnancy: 778 x Performed locally for females of child-bearing potential at Screening, randomization (if 779 not performed within the prior 6 days) and at the beginning of the second study period [ADDRESS_804151] may also be performed at any time pregnancy is 781 suspected. 782 9.2 Questionnaires 783 The following questionnaires will be completed at Screening and at the end of each 13-week 784 periods during the crossover trial (except for the SUS survey, which will only be administered 785 after the AID period, and the INSPI[INVESTIGATOR_179563], which will only be administered at Screening and 786 after the AID period). Final questionnaires also may be collected for participants who withdraw [ADDRESS_804152] Measured/Relevant Points  Diabetes Distress Scale  Gold standard measure for understanding distress symptoms related to diabetes. 
A recently validated version for adults with T1D, but will also be administered 
to adolescents (17 items; 6 min)  Glucose Monitoring Satisfaction  Survey  This recently validated survey is an outgrowth of DirecNet  and JDRF CGM 
surveys; evaluates treatment satisfaction and burden. Administered to all 
participants (15 items; 4 min)  Hypoglycemia Confidence  Includes 8 different common situations where hypoglycemia occurs (e.g., 
physical activity, driving) and evaluates level of confidence in those situations 
(8 items; 3 min)  
 
DCLP4 PROTOCOL V6.[ADDRESS_804153] Measured/Relevant Points  Diabetes Technology Attitudes  Subjective  questions about attitudes related to diab etes technologies and 
devices (5  items; 3 min)  INSPI[INVESTIGATOR_606941]. Adult 
survey has 22 items; adolescent version 17  items. (6 -8 mins)  System Usability Scale (SUS)  A 10-item questionnaire that measures the overall usability of a system. 
It is a valid and reliable measure of the perceived usability of a sys tem 
and is technology -agnostic.   792 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 46 OF 68 Chapter 10: Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869] [ADDRESS_804154] be reported to 796 the JCHR IRB within 7 calendar days of recognition.   797 For this protocol, an unanticipated problem is an incident, experience, or outcome that meets all 798 of the following criteria: 799 x Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures 800 that are described in the protocol related documents, such as the IRB-approved research 801 protocol and informed consent document; and (b) the characteristics of the subject 802 population being studied 803 x Related or possibly related to participation in the research (possibly related means there is [ADDRESS_804155] been caused 805 by [CONTACT_3459]) 806 x Suggests that the research places participants or others at a greater risk of harm than was 807 previously known or recognized (including physical, psychological, economic, or social 808 harm) 809 The Coordinating Center also will report to the IRB all unanticipated problems not directly 810 involving a specific site such as unanticipated problems that occur at the Coordinating Center or 811 at another participating entity such as the central laboratory. 812 10.2 Adverse Events 813 10.2.1 Definitions 814 Adverse Event (AE): Any untoward medical occurrence in a study participant, irrespective of the 815 relationship between the adverse event and the device(s) under investigation. 816 Serious Adverse Event (SAE): Any untoward medical occurrence that: 817 x Results in death. 818 x Is life-threatening; (a non-life-threatening event which, had it been more severe, might [ADDRESS_804156] become life-threatening, is not necessarily considered a serious adverse event). 820 x Requires inpatient hospi[INVESTIGATOR_1081]. 821 x Results in persistent or significant disability/incapacity or substantial disruption of the [ADDRESS_804157] normal life functions (sight threatening). [ADDRESS_804158]. 824 x Is considered a significant medical event by [CONTACT_13656] 825 (e.g., may jeopardize the participant or may require medical/surgical intervention to 826 prevent one of the outcomes listed above). [ADDRESS_804159] (UADE): Any serious adverse effect on health or safety or [ADDRESS_804160], 829 problem, or death was not previously identified in nature, severity, or degree of incidence in the 830 investigational plan or application (including a supplementary plan or application), or any other 831 unanticipated serious problem associated with a device that relates to the rights, safety, or 832 welfare of participants (21 CFR 812.3(s)). [ADDRESS_804161] (ADE): Any untoward medical occurrence in a study participant which a [ADDRESS_804162] contributed (note that an Adverse 835 Event Form is to be completed in addition to a Device Deficiency or Issue Form, unless excluded 836 from reporting as defined in ). An event that occurs solely due to participant (i.e., user) error in 837 which the device functions properly generally will not be considered an ADE unless it is 838 determined that the instructions on the screen of the device or user manual (or similar training 839 materials) may have contributed to the event (note: the event may still meet criteria for reporting 840 as an adverse event). 841 Device Complaints and Malfunctions: A device complication or complaint is something that 842 happens to a device or related to device performance, whereas an adverse event happens to a 843 participant.  A device complaint may occur independently from an AE, or along with an AE.  An 844 AE may occur without a device complaint or there may be an AE related to a device complaint.  845 A device malfunction is any failure of a device to meet its performance specifications or 846 otherwise perform as intended.  Performance specifications include all claims made in the 847 labeling for the device.  The intended performance of a device refers to the intended use for 848 which the device is labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, sites will [ADDRESS_804163] medical occurrence that 852 meets one of the following criteria: 853 x An SAE 854 x An ADE as defined in section 10.2.1, unless excluded from reporting in section 10.3 855 x An AE as defined in 10.2.1 occurring in association with a study procedure 856 x An AE as defined in 10.2.1 not related to a device issue which leads to temporary or 857 permanent discontinuation of  a study device 858 x An AE as defined in 10.2.1 WKDWDIIHFWVWKHSDUWLFLSDQWÂ¶VDELOLW\WRFRPSOHWHDQ\VWXdy 859 procedures 860 x An AE as defined in 10.2.1 for which a visit is made to a hospi[INVESTIGATOR_3409] 861 x Hypoglycemia meeting the definition of severe hypoglycemia as defined below 862 x Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, hyperglycemia [ADDRESS_804164].  Skin reactions from sensor placement 866 are only reportable if severe and/or required treatment. [ADDRESS_804165] is only reportable as an adverse 873 event when the following definition for severe hypoglycemia is met: the event required 874 assistance of another person due to altered consciousness, and required another person to actively 875 administer carbohydrate, glucagon, or other resuscitative actions.  This means that the participant 876 was impaired cognitively to the point that he/she was unable to treat himself/herself, was unable 877 to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure [ADDRESS_804166] to reporting requirements. 886 10.2.4 Hyperglycemia/Ketosis Events [ADDRESS_804167] is only reportable as an adverse 888 event when one of the following 3 criteria is met: 889 x The event involved DKA, as defined by [CONTACT_3467] 890 (DCCT) and described below 891 x Evaluation or treatment was obtained at a health care provider facility for an acute event 892 involving hyperglycemia or ketosis, or the participant contact[CONTACT_3466] 893 guidance on how to manage the hyperglycemia/ketosis 894 x %ORRGNHWRQHOHYHOÂ•PPRO/HYHQ if there was no communication with a health care 895 provider at the time of the event 896 Hyperglycemic events are classified as DKA if the following are present: 897 x Symptoms such as polyuria, polydipsia, nausea, or vomiting; 898 x Serum ketones >1.5 mmol/L or large/moderate urine ketones; 899 x Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO2) <15; 900 and 901 x Treatment provided in a health care facility. 902 When a hyperglycemia/ketotic event meets the above reporting requirements, a Hyperglycemia/ [ADDRESS_804168] been caused 910 by [CONTACT_19911]. 911 To ensure consistency of adverse event causality assessments, investigators should apply the 912 following general guideline when determining whether an adverse event is related: 913 Yes 914 There is a plausible temporal relationship between the onset of the adverse event and the study 915 intervention, and the adverse event cannot be readily explDLQHGE\WKHSDUWLFLSDQWÂ¶VFOLQLFDOVWDWH916 intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the adverse event follows a known pattern 917 of response to the study intervention; and/or the adverse event abates or resolves upon 918 discontinuation of the study intervention or dose reduction and, if applicable, reappears upon re 919 challenge. 920 No 921 Evidence exists that the adverse event has an etiology other than the study intervention (e.g., 922 preexisting medical condition, underlying disease, intercurrent illness, or concomitant 923 medication); and/or the adverse event has no plausible temporal relationship to study 924 intervention. 925 10.2.6 Severity (Intensity) of Adverse Events 926 The severity (intensity) of an adverse event will be rated on a three point scale: (1) mild, 927 (2) moderate, or (3) severe.  A severity assessment is a clinical determination of the intensity 928 of an event.  Thus, a severe adverse event is not necessarily serious.  For example, itching for 929 several days may be rated as severe, but may not be clinically serious. 930 x MILD: Usually transient, requires no special treatment, and does not interfere with the 931 SDUWLFLSDQWÂ¶VGDLO\DFWLYLWLHV 932 x MODERATE: Usually causes a low level of inconvenience, discomfort or concern to the 933 participant and may interfere with daily activities, but is usually ameliorated by [CONTACT_3469] 934 therapeutic measures and participant is able to continue in study. 935 x 6(9(5(,QWHUUXSWVDSDUWLFLSDQWÂ¶VXVXDOGDLO\DFWLYLWLHVFDXVHVVHYHUHGLVFRPI[INVESTIGATOR_13318]PD\936 cause discontinuation of study device, and generally requires systemic drug therapy or 937 other treatment. 938 10.2.7 Expectedness 939 For a serious adverse event that is considered possibly related to study device, the Medical 940 Monitor will classify the event as unexpected if the nature, severity, or frequency of the event 941 is not consistent with known risk information. 942 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 50 OF 68 10.2.8 Coding of Adverse Events 943 Adverse events will be coded using the MedDRA dictionary. To facilitate coding, the site will 944 enter a preliminary MedDRA code which the Medical Monitor may accept or change (the 945 Medical MonitRUÂ¶V0HG'5$FRGLQJZLOOEHXVHGIRUDOOUHSRUWLQJ7KH0HGLFDO0RQLWRUZLOO946 UHYLHZWKHLQYHVWLJDWRUÂ¶VDVVHVVPHQWRIFDXVDOLW\DQGPD\DJUHHRUGLVDJUHH%RWKWKH947 LQYHVWLJDWRUÂ¶VDQG0HGLFDO0RQLWRUÂ¶VDVVHVVPHQWVZLOOEHUHFRUGHG7KH0HGLFDO0RQLWRUZLOO [ADDRESS_804169] the final say in determining the causality as well as whether an event is classified as a 949 serious adverse event and/or an unanticipated adverse device effect. 950 10.2.9 Outcome of Adverse Events 951 The outcome of each reportable adverse event will be classified by [CONTACT_3470]: 952 x RECOVERED/RESOLVED: The participant recovered from the AE/SAE without [ADDRESS_804170] the AE/SAE stop date. 954 x RECOVERED/RESOLVED WITH SEQUELAE: The event persisted and had stabilized [ADDRESS_804171] the AE/SAE stop date. 956 x FATAL: A fatal outcome is defined as the SAE that resulted in death.  Only the event that 957 was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the 958 time of death; however, were not the cause of deatKZLOOEHUHFRUGHGDVÂ³UHVROYHGÂ´DWWKH959 time of death. 960 x NOT RECOVERED/NOT RESOLVED (ONGOING): An ongoing AE/SAE is defined as 961 the event was ongoing with an undetermined outcome. 962 An ongoing outcome will require follow-up by [CONTACT_595078] 963 the AE/SAE. 964 The outcome of an ongoing event at the time of death that was not the cause of death, will be 965 XSGDWHGDQGUHFRUGHGDVÂ³UHVROYHGÂ´ZLWKWKHGDWHRIGHDWKUHFRUGHGDVWKHVWRSGDWH 966 UNKNOWN: An unknown outcome is defined as an inability to access the participant or the 967 SDUWLFLSDQWÂ¶VUHFRUGVWRGHWHUPLQHWKHRXWFRPHIRUH[DPSOHDSDUWLFLSDQWWKDWZDVORVWWR968 follow-up). 969 If any reported adverse events are ongoing when a participant completes the study (or 970 withdraws), adverse events classified UADEs will be followed until they are either resolved, or [ADDRESS_804172] of improvement or change, even after the participant has completed all 972 applicable study visits/contacts.  For all other adverse events, data collection will end at the time 973 the participant completes the study. Note: participants should continue to receive appropriate 974 medical care for an adverse event after their participation in the study ends. 975 10.3 Reportable Device Issues 976 All UADEs and ADEs as defined in section 10.2.1 will be reported on both a device issue form 977 and AE form, except for skin reactions from CGM sensor placement or pump infusion set 978 placement that do not require pharmacologic treatment. As noted in section 10.2.1, events that 979 occur due to participant (user) error generally will not require completion of a device issue form. 980 6XFKÂµHUURUVÂ¶FRXOGLQFOXGHLPSURSHUXVHRIDQLQVXOLQSXPSRUXVLQJDSXPSLQIXVLRQVHWRU[ADDRESS_804173] not been met: 985 x CGM sensor lasting fewer days than expected per manufacturer 986 x CGM tape adherence issues 987 x Battery lifespan deficiency due to inadequate charging or extensive wireless 988 communication 989 x Intermittent device component disconnections/communication failures not requiring 990 system replacement or workaround/resolution not specified in user guide/manual [ADDRESS_804174] be reported to 995 the Coordinating Center within 24 hours of the site becoming aware of the event.  This can occur 996 via phone or email, or by [CONTACT_263240] 997 form if applicable.  If the form is not initially completed, it should be competed as soon as 998 possible after there is sufficient information to evaluate the event. All other reportable ADEs and 999 other reportable AEs should be submitted by [CONTACT_606950] 7 days of the 1000 site becoming aware of the event. 1001 The Coordinating Center will notify all participating investigators of any adverse event that is 1002 serious, related, and unexpected.  Notification will be made within 10 days after the 1003 Coordinating Center becomes aware of the event. 1004 Each principal investigator [INVESTIGATOR_3411]-related adverse events and 1005 abiding by [CONTACT_66716]/her Institutional Review Board or [ADDRESS_804175] be informed of all UADEs within seven calendar days. 1007 Upon receipt of a UADE report, the Sponsor will investigate the UADE and if indicated, report 1008 the results of the investigation to all overseeing IRBs, and the FDA within 10 working days of 1009 the Sponsor becoming aware of the UADE per 21CFR 812.46(b) (2).  The Medical Monitor must [ADDRESS_804176] receipt notice of the UADE. 1014 Device malfunctions will be handled by [CONTACT_263243].  In the case 1015 of a CGM transmitter or sensor device malfunction, information will be forwarded to Dexcom by 1016 the site personnel, to be handled by [CONTACT_468516]. 1017 10.5 Safety Oversight 1018 The study Medical Monitor will review all adverse events and adverse device events that are 1019 reported during the study.  SAEs typi[INVESTIGATOR_66684] 24 hours of reporting.  Other 1020 AEs typi[INVESTIGATOR_3413] a weekly basis. Additionally, the Medical Monitor will review 1021 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 52 OF 68 compi[INVESTIGATOR_27985] (generally timed to the review of compi[INVESTIGATOR_120712] 1022 by [CONTACT_4318]). 1023 The Clinical Study Director will be informed of all cases of severe hypoglycemia and DKA and 1024 the Medical MonLWRUÂ¶VDVVHVVPHQWRIUHODWLRQVKLSWRWKHVWXG\GHYLFHDQGLQIRUPHGRIDOO[ADDRESS_804177] (DSMB) will provide safety oversight.  The DSMB will be [ADDRESS_804178] modifications to the study protocol or suspension or outright stoppage of 1032 the study if deemed necessary based on the totality of safety data available.  Details regarding the 1033 '60%Â¶VUROHZLOOEHGRFXPHQWHGLQDVHSDUDWH'60%GRFXPHQW 1034 10.6 Stoppi[INVESTIGATOR_2121] 1035 10.6.1 Participant Discontinuation of Study Device 1036 In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA 1037 event (or a malfunction that could have led to severe hypoglycemia or DKA), use of the study 1038 system will be suspended while the problem is diagnosed. The UADE will be reported to the 1039 IRB, DSMB, and FDA. After assessment of the problem and any correction, use of the system 1040 will not be restarted until approval is received from the IRB, DSMB, and FDA. 1041 In the absence of a device malfunction, use of the study system by a participant will be 1042 discontinued if any of the following occur: 1043 x The investigator believes it is unsafe for the participant to continue on the intervention.  1044 This could be due to the development of a new medical condition or worsening of an 1045 existing condition; or participant behavior contrary to the indications for use of the device 1046 WKDWLPSRVHVRQWKHSDUWLFLSDQWÂ¶VVDIHW\ [ADDRESS_804179] to determination of cause and whether the occurrence of the event can be 1055 attributed to use of the study system. 1056 An additional requirement for continued [study device] use following a single DKA or severe 1057 hypoglycemia event will be that (1) the site investigator believes that the event is explainable, 1058 unlikely to recur, and that it is safe for the participant to continue to use the system and (2) the 1059 Medical Monitor and DSMB concur. If either the Medical Monitor or DSMB determines that the 1060 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 53 OF 68 occurrence of the event indicates that it is not safe for the participant to continue to use the BP 1061 system, use will be discontinued. 1062 10.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] 1063 In addition to the suspension of device use due to a UADE as described in 10.6.1, study activities 1064 could be similarly suspended if the manufacturer of any constituent study device requires 1065 stoppage of device use for safety reasons (e.g. product recall).  In addition to suspension of 1066 device use due to a UADE, the study will be suspended for 2 severe hypoglycemia and/or DKA [ADDRESS_804180] suspension of study activities or stoppage of the 1071 study at any time if deemed necessary based on the totality of safety data available. 1072  1073 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 54 OF 68 Chapter 11: Miscellaneous Considerations 1074 11.1 Drugs Used as Part of the Protocol 1075 U-100 rapid acting insulin analogues, Aspart or Lispro, will be used during the study since these 1076 are the only insulins approved for the study pump. 1077 11.2 Collection of Medical Conditions and Medications 1078 Pre-Existing Condition: Any medical condition that is either present at screening, a chronic 1079 disease, RUDSULRUFRQGLWLRQWKDWFRXOGLPSDFWWKHSDUWLFLSDQWÂ¶VKHDOWKGXULQJWKHFRXUVHRIWKH1080 study (e.g., prior myocardial infarction or stroke). 1081 Medical Conditions during the study: The following medical conditions that do not qualify for 1082 reporting on an Adverse Event Form should be reported on the Medical Conditions Form: (1) 1083 new diagnosis of a chronic disease (i.e., not present at the time of enrollment) and (2) any 1084 PHGLFDOFRQGLWLRQWKDWFRXOGDIIHFWWKHSDUWLFLSDQWÂ¶VDELOLW\WRFDUU\RXWDQ\DVSHFWRIWKHprotocol 1085 RUFRXOGDIIHFWDQRXWFRPHDVVHVVPHQW7UDQVLHQWFRQGLWLRQVWKDWGRQRWDIIHFWWKHSDUWLFLSDQWÂ¶V1086 ability to carry out the protocol or study data related to any study outcome do not need to be 1087 reported. 1088 Medications: All medications that the participant is currently taking at screening and during the 1089 course of the study should be recorded.  Nutraceuticals and preventative treatment also should be 1090 recorded.  This will include the treatment of chronic pre-existing conditions, medical conditions 1091 that occur during the study (both reportable and not-reportable medical conditions), and/or 1092 adverse events. Medications only taken as needed either can be recorded when prescribed or only 1093 recorded if used during the study.  Glucagon for treatment of severe hypoglycemia will only be 1094 recorded if used during the study. 1095 11.3 Prohibited Medications, Treatments, and Procedures 1096 Participants are not permitted to use Afrezza or any non-insulin glucose-lowering agent other 1097 than metformin (including GLP-1 agonists, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 1098 Participants are not permitted to use diabetes management devices that are not FDA approved 1099 (such as do-it-yourself closed-loop systems). [ADDRESS_804181] a commercially available glucagon (or glucagon analog) [ADDRESS_804182] final study data. 1113 If participants wish to discontinue using the study device without withdrawing, participants will 1114 be encouraged to remain in the study through the final study visit. 1115 11.8 Confidentiality 1116 For security and confidentiality purposes, participants will be assigned an identifier that will be 1117 used instead of their name. Protected health information gathered for this study will be shared 1118 with the coordinating center, the Jaeb Center for Health Research in Tampa, FL. De-identified 1119 participant information may also be provided to research sites involved in the study. 1120  1121 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 56 OF 68 Chapter 12: Statistical Considerations [ADDRESS_804183] tabulation of data by [CONTACT_1570] 1125 (i.e., for DSMB review).   1126 12.2 Statistical Hypotheses 1127 The primary outcome for this study is CGM-measured % in range 70-180 mg/dL over 12 weeks 1128 in each one of the two crossover periods. The intervention will be considered effective if time in 1129 range during the CLC period is superior to the SAP period using a statistical significance of 1130 Ä® and the model specified below (section 12.6). 1131 The null/alternative hypotheses are: 1132 a. Null Hypothesis: There is no difference in mean CGM-measured % in range 70-180 1133 mg/dL over 12 weeks between SAP and CLC periods 1134 b. Alternative Hypothesis: The mean CGM-measured % in range 70-180 mg/dL over 12 1135 weeks is different for SAP and CLC periods. 1136 12.3 Sample Size 1137 Sample size has been computed for the primary outcome (CGM-measured % in range 70-180 1138 mg/dL). Data from the SAP group in DCLP3 (The International Diabetes Closed Loop Protocol 3 1139 Pi[INVESTIGATOR_498292] t:slim X2 with Control-IQ Technology) were used to calculate sample size specific 1140 to Â•[ADDRESS_804184] deviation for time in range 70-180 mg/dL [ADDRESS_804185] 3 months was 12% (95% CI 10% to 16%) and the correlation between [ADDRESS_804186] 3 months was 0.92. 1143 A total sample size was computed to be N=31 for the following assumptions: (1) two 3-month 1144 periods [CLC:SAP] crossover randomization, (2) 90% power, (3) a 8% absolute increase in % 1145 time in range 70-180 mg/dL, (4) a SD of 17%, (5) a correlation between the two periods of 0.70, 1146 and (6) 2-sided type 1 error of 0.05. 1147 The total sample size has been increased to N=35 to account for potential dropouts.  1148 12.4 Outcome Measures 1149 12.4.1 Primary Efficacy Endpoint 1150 CGM-measured % in range 70-180 mg/dL 1151 12.4.2 Secondary Efficacy Endpoints 1152 [IP_ADDRESS] Secondary Efficacy Endpoint Included in Hierarchical Analysis 1153 CGM-measured % below 54 mg/dL (non-inferiority outcome with a non-inferiority limit of 1154 1.0%) will be tested in a hierarchical fashion as described in section 12.7.1. This is the only non-1155 inferiority outcome in the study; all others are superiority. 1156 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 57 OF 68 [IP_ADDRESS] Other Secondary Efficacy Endpoints 1157 The following endpoints are considered exploratory. 1158 CGM-Measured: 1159 x % in range 70-140 mg/dL 1160 x mean glucose 1161 x glucose variability measured with the coefficient of variation (CV) [ADDRESS_804187] deviation (SD) 1163 x % <70 mg/dL 1164 x % <60 mg/dL 1165 x % <54 mg/dL  1166 x low blood glucose index 1167 x hypoglycemia events (defined as at least 15 consecutive minutes <70 mg/dL) 1168 x % >180 mg/dL 1169 x % >250 mg/dL 1170 x % >300 mg/dL  1171 x high blood glucose index 1172 x CGM metrics by [CONTACT_55413]. Calculate all CGM metrics listed above (including the 1173 primary outcome) for: 1174 Â¡ All 24 hours of the day  1175 Â¡ Daytime only (06:00AM to 00:00AM) 1176 Â¡ Nighttime only (00:00AM to 06:00AM) 1177 HbA1c: 1178 x HbA1c at 13 weeks 1179 x HbA1c <7.0% at 13 weeks 1180 x HbA1c <7.5% at 13 weeks 1181 x HbA1c improvement from baseline to 13 weeks >0.5% 1182 x HbA1c improvement from baseline to 13 weeks >1.0% 1183 x HbA1c relative improvement from baseline to 13 weeks >10% 1184 Questionnaires: 1185 x Diabetes Distress Scale at 13 weeks Â± total score and 4 subscales: 1186 Â¡ Emotional burden 1187 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 58 OF 68 Â¡ Physician-related distress 1188 Â¡ Regimen-related distress 1189 Â¡ Interpersonal distress 1190 x Glucose Monitoring Satisfaction Survey Â± satisfaction, burden, and total scores 1191 x Hypoglycemia Confidence Scale 1192 x Diabetes Technology Attitudes survey 1193 x INSPI[INVESTIGATOR_367219] - following study system period only 1194 x SUS survey scores - following study system period and at 13 weeks only 1195 Other: 1196 x Insulin at 13 weeks 1197 Â¡ Total daily insulin (units/kg) 1198 Â¡ Basal: bolus insulin ratio 1199 x Weight and Body Mass Index (BMI) at [ADDRESS_804188] 72hr of 1207 CGM data at baseline and in each one of the two periods are needed in order for the metrics to be 1208 calculated. 1209 12.5 Analysis Datasets and Sensitivity Analyses 1210 All analyses comparing the CLC period with SAP period will follow the intention-to-treat (ITT) [ADDRESS_804189] 72hr of CGM data will be included in the primary and 1213 secondary hierarchical analyses. 1214 Safety outcomes will be reported for all enrolled participants, irrespective of whether the 1215 participant was randomized or the study was completed. 1216 12.5.1 Per Protocol Analyses 1217 x If more than 10% of participants in a treatment period have fewer than 168 hours of CGM 1218 data, the primary analysis will be replicated excluding such subjects. 1219 x The primary analysis will be replicated only with participants who used the system in CL 1220 mode for >80% during the CLC period and used the sensor for >80% during the SAP 1221 period. 1222 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 59 OF 68 12.5.2 Sensitivity Analyses  1223 [IP_ADDRESS] Missing Data 1224 It is worth emphasizing that any statistical method for handling missing data makes a number of 1225 untestable assumptions.  The goal will be to minimize the amount of missing data in this study so 1226 that results and conclusions will not be sensitive to which statistical method is used. To that end, 1227 sensitivity analyses will be performed to explore whether results are similar for primary analysis 1228 when using different methods.  The following methods will be applied: 1229 x $YDLODEOHFDVHVRQO\Â•KULQDWOHDVWRQHRIWKHWZRFURVV-over periods, primary analysis 1230 described below) 1231 x 5XELQÂ¶VPXOWLSOHLPSXWDWLRQ 1232 [IP_ADDRESS] Carry-over Effect [ADDRESS_804190] for any carry-over effects, by [CONTACT_1583] a 1234 treatment by [CONTACT_606951]. 1235 12.6 Analysis of the Primary Efficacy Endpoint 1236 Summary statistics [mean Â± SD or median (IQR)] will be reported for the CGM-measured % in 1237 range 70-180 mg/dL and for baseline and two randomized cross-over periods. 1238 A repeated measures linear regression model will be fit for CGM-measured % in range 70-180 1239 mg/dL. The model will include pre-randomization baseline, the two cross-over periods, and will [ADDRESS_804191] for period and site (as random effect). Residual values will be examined for an [ADDRESS_804192] 1242 statistical method (e.g., non-parametric or MM estimation) will be used instead. It is expected 1243 that the residual values for CGM-measured % in range 70-180 mg/dL will follow an approximate 1244 normal distribution. 1245 12.7 Analysis of the Secondary Endpoints 1246 Point estimates and confidence intervals for the treatment period differences will be presented 1247 for all secondary metrics. Models similar with the one described above will be implemented. 1248 12.7.1 Hierarchical Analyses 1249 To preserve the overall type 1 error for CGM-measured % below 54 mg/dL, a hierarchical 1250 testing procedure will be used. A formal statistical assessment of non-inferiority (limit 1%) for 1251 time below 54 mg/dl will only be performed if the primary analysis for time in range described 1252 above results in a statistically significant result (p < 0.05). 1253 Regardless of the results for the primary outcome, summary statistics appropriate to the 1254 distribution will be tabulated by [CONTACT_606952]-measured non-inferiority % below 54 1255 mg/dL.  However, the reported one-sided 95% confidence interval for CGM-measured % below 1256 54 mg/dL that excludes the non-inferiority limit of 1.0% will not be considered a statistically 1257 significant result if the primary outcome failed to reach statistical significance. 1258 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 60 OF 68 12.7.2 Other Endpoint Analyses 1259 CGM-Measured Outcomes 1260 The analyses for the secondary CGM-measured outcomes will parallel those mentioned above 1261 for the primary outcome. 1262 HbA1c 1263 Summary statistics [mean Â± SD or median (IQR)] will be reported for the central lab HbA1c at 1264 randomization and 13 weeks in each treatment period. 1265 Lab HbA1c values at 13 weeks will be compared between the two treatment periods using a 1266 linear model while adjusting for period, site (random effect), and baseline value.  [ADDRESS_804193] for the same 1269 factors mentioned above for the analysis with HbA1c as a continuous factor (i.e., period, site, 1270 and baseline value). 1271 Questionnaires and Other Outcomes 1272 For questionnaires administered during both randomization periods, comparisons will be made 1273 using similar linear models as described above for the primary outcomes. Separate models will 1274 be run for the total score and each of the subscales listed above. 1275 Similarly, for insulin, weight and BMI metrics comparisons will be made using similar linear 1276 models as described above for the primary HbA1c analysis. 1277 12.8 Safety Analyses 1278 All enrolled participants will be included in these analyses and all their safety events will be 1279 reported. 1280 The circumstances of all reportable cases of the following will be summarized and tabulated by 1281 treatment period: 1282 x Severe hypoglycemia  1283 x Diabetic ketoacidosis  1284 x .HWRQHHYHQWVGHILQHGDVGD\ZLWKNHWRQHOHYHOÂ•PPRO/ 1285 x CGM-PHDVXUHGK\SRJO\FHPLFHYHQWVÂ•PLQXWHVZLWKJOXFRVHFRQFHQWUDWLRQ1286 mg/dL) 1287 x CGM-PHDVXUHGK\SHUJO\FHPLFHYHQWVÂ•PLQXWHVZLWKJOXFRVHFRQFHQWUDWLRQ!1288 mg/dL) 1289 x Worsening of HbA1c from start of the period to 13 weeks by >0.5% 1290 x Other serious adverse events (SAE) and serious adverse device events (SADE) 1291 x Adverse device effects (ADE) 1292 x Unanticipated adverse device effects (UADE) [ADDRESS_804194] Poisson regression. The amount of follow up will be included as an offset covariate to 1297 compare the rates. 1298 Comparison of safety outcomes between the two treatment periods only include those events 1299 occurring on or after randomization until the final 13 week visit.  1300 Any pre-randomization adverse events will be tabulated separately and will include participants 1301 who were never randomized. 1302 12.9 Intervention Adherence and Adaptation 1303 The following tabulations and analyses will be performed by [CONTACT_606953] 1304 intervention adherence for the study: 1305 x Sensor use Â±percent time of use, overall and by 4-weekly 1306 x The overall daily frequency of downloaded BGM use  1307 x For CLC period only, the following will be tabulated: 1308 Â¡ Percent time in different operational modes - overall and by [CONTACT_24473] 1309 Â¡ Percent change of clinical and controller adaptation parameters throughout closed-loop 1310 use 1311 12.10 Adherence and Retention Analyses 1312 The following tabulations and analyses will be performed by [CONTACT_606954] 1313 adherence for the study: [ADDRESS_804195] 1330 modifications to the study protocol or suspension or outright stoppage of the study if deemed 1331 necessary. 1332 12.14 Subgroup Analyses 1333 In exploratory analyses, the primary outcome will be assessed separately with tests of interaction 1334 in various subgroups and for continuous variables according to the baseline value, which will be 1335 described in the Statistical Analysis Plan. 1336 12.15 Multiple Comparison/Multiplicity 1337 Hierarchical testing will be done to control the type 1 error for the time in range and time below 1338 54 mg/dl outcomes as described above in Section 12.7.1. 1339 No multiplicity adjustment will be done for safety analyses.  For all other secondary analyses, 1340 the false discovery rate will be controlled using the adaptive Benjamini-Hochberg procedure. 1341  1342 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 63 OF 68 Chapter 13: Data Collection and Monitoring 1343 13.1 Case Report Forms and Device Data 1344 The main study data are collected on electronic case report forms (CRFs). When data are directly 1345 collected in electronic case report forms, this will be considered the source data. For any data 1346 points for which the eCRF is not considered source (e.g. lab results that are transcribed from a 1347 printed report into the eCRF), the original source documentation must be maintained in the 1348 SDUWLFLSDQWÂ¶VVWXG\FKDUWRUPHGLFDOUHFRUG7KLVVRXUFHPXVWEHUHDGLO\YHULILDEOHDJDLQVWWKH[ADDRESS_804196] be recorded (e.g., office note, visit record, 1351 etc.). [ADDRESS_804197]. These documents should 1362 be retained for a longer period, however, if required by [CONTACT_427]. No records will be 1363 destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the 1364 sponsor to inform the investigator when these documents no longer need to be retained. 1365 13.3 Quality Assurance and Monitoring 1366 Designated personnel from the Coordinating Center will be responsible for maintaining quality 1367 assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1368 conducted and data are generated, documented and reported in compliance with the protocol, 1369 Good Clinical Practice (GCP) and the applicable regulatory requirements, as well as to ensure 1370 that the rights and wellbeing of trial participants are protected and that the reported trial data are 1371 accurate, complete, and verifiable. Adverse events will be prioritized for monitoring. 1372 A risk-based monitoring (RBM) plan will be developed and revised as needed during the course 1373 RIWKHVWXG\FRQVLVWHQWZLWKWKH)'$Â³*XLGDQFHIRU,QGXVWU\2YHUVLJKWRI&OLQLFDO1374 Investigations Â± A Risk-%DVHG$SSURDFKWR0RQLWRULQJÂ´$XJXVW6WXG\FRQGXFWDQG1375 monitoring will conform with 21 Code of Federal Regulations (CFR) 812. This plan describes in [ADDRESS_804198] importance for monitoring at the site are participant eligibility and adverse 1379 events. Therefore, the RBM plan will focus on these areas. As much as possible, remote 1380 monitoring will be performed in real-time with on-site monitoring performed to evaluate the 1381 verity and completeness of the key site data. Elements of the RBM may include: [ADDRESS_804199] (IRB) coverage and informed consent procedures 1384 x Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol 1385 review of entered data and edits, statistical monitoring, study closeout 1386 x On-site monitoring (site visits): source data verification, site visit report [ADDRESS_804200] access to all trial related sites, source 1398 data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and 1399 inspection by [CONTACT_3482]. 1400 13.4 Protocol Deviations 1401 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1402 requirements.  The noncompliance may be either on the part of the participant, the investigator, 1403 or the study site staff.  As a result of deviations, corrective actions are to be developed by [CONTACT_779] 1404 and implemented promptly. 1405 The site PI/study staff is responsible for knowing and adhering to their IRB requirements. 1406 Further details about the handling of protocol deviations will be included in the monitoring plan. 1407  1408 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 65 OF 68 Chapter 14: Ethics/Protection of Human Participants [ADDRESS_804201] 1410 The investigator will ensure that this study is conducted in full conformity with Regulations for 1411 the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 1412 21 CFR Part 56, and/or the ICH E6. [ADDRESS_804202] (IRB) (or Ethics Committee (EC)) 1414 The protocol, informed consent form(s), recruitment materials, and all participant materials will 1415 be submitted to the IRB/EC for review and approval. Approval of both the protocol and the [ADDRESS_804203] be obtained before any participant is enrolled. Any amendment to the 1417 protocol will require review and approval by [CONTACT_1201]/EC before the changes are implemented to 1418 the study. All changes to the consent form will be IRB/EC approved; a determination will be 1419 made regarding whether previously consented participants need to be re-consented. 1420 14.3 Informed Consent Process 1421 14.3.1 Consent Procedures and Documentation 1422 Informed consent is a process that is initiated priRUWRWKHLQGLYLGXDOÂ¶VDJUHHLQJWRSDUWLFLSDWHLQ1423 WKHVWXG\DQGFRQWLQXHVWKURXJKRXWWKHLQGLYLGXDOÂ¶VVWXG\SDUWLFLSDWLRQ([WHQVLYHGLVFXVVLRQRI1424 risks and possible benefits of participation will be provided to the participants and their families. 1425 Consent forms will be IRB/EC-approved and the participant will be asked to read and review the [ADDRESS_804204] by [CONTACT_3486], their staff, 1440 and the Coordinating Center(s) and their agents. This confidentiality is extended to cover testing [ADDRESS_804205] party without prior written approval of the Steering Committee. 1445 The study monitor, other authorized representatives of the Coordinating Center, representatives 1446 of the IRB/EC or device company supplying study product may inspect all documents and 1447 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 66 OF 68 records required to be maintained by [CONTACT_093], including but not limited to, medical 1448 records (office, clinic, or hospi[INVESTIGATOR_307]) for the participants in this study. The clinical study site will 1449 permit access to such records. 1450 7KHVWXG\SDUWLFLSDQWÂ¶VFRQWDFWLQIRUPDWLRQZLOOEHVHFXUHO\VWRUHGDWHDFKFOLQLFDOVLWHIRU1451 internal use during the study. At the end of the study, all records will continue to be kept in a 1452 secure location for as long a period as dictated by [CONTACT_606955]/national 1453 regulations. 1454 Study participant research data, which is for purposes of statistical analysis and scientific 1455 reporting, will be transmitted to and stored either at the Jaeb Center for Health Research (JCHR) [ADDRESS_804206] uses a cloud-1457 based provider for storage of the closed-loop system data. These data will not include the 1458 SDUWLFLSDQWÂ¶VFRQWDFWRULGHQWLI\LQJLQIRUPDWLRQXQOHVVRWKHUZLVHVSHFLILHGLQWKHLQIRUPHG[ADDRESS_804207] access to research records to refuse to 1467 disclose identifying information on research participation in any civil, criminal, administrative, 1468 legislative, or other proceeding, whether at the federal, state, or local level. By [CONTACT_263254] 1469 researchers and institutions from being compelled to disclose information that would identify 1470 research participants, Certificates of Confidentiality help achieve the research objectives and 1471 promote participation in studies by [CONTACT_4205][INVESTIGATOR_21783]. 1472  1473 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 67 OF 68 Chapter 15: References 1. Dassau E, Zisser H, Harvey RA, Percival MW, Grosman B, Bevier W, Atlas E, Miller S, 1LPUL5-RYDQRYLÃ¾ L, Doyle III FJ. Clinical Evaluation of a Personalized Artificial Pancreas. Diabetes Care. 2013;36:801-9. doi: 10.2337/dc12-0948. 2. Dassau E, Brown SA, Basu A, Pi[INVESTIGATOR_45905], Kudva YC, Gondhalekar R, Patek S, Lv D, Schiavon M, Lee JB, Dalla Man C, Hinshaw L, Castorino K, Mallad A, Dadlani V, McCrady-Spi[INVESTIGATOR_212371], McElwee-Malloy M, Wakeman CA, Bevier WC, Bradley PK, Kovatchev B, Cobelli C, Zisser HC, Doyle III FJ. Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial. J Clin Endocrinol Metab. 2015;100(10):3878-86. Epub 2015/07/24. doi: 10.1210/jc.2015-2081. PubMed PMID: 26204135; PMCID: PMC4596045. 3. Dassau E, Pi[INVESTIGATOR_45905], Kudva YC, Brown SA, Gondhalekar R, Dalla Man C, Patek S, Schiavon M, Dadlani V, Dasanayake I, Church MM, Carter RE, Bevier WC, Huyett LM, Hughes J, Anderson S, Lv D, Schertz E, Emory E, McCrady-Spi[INVESTIGATOR_212371], Jean T, Bradley PK, Hinshaw L, Laguna Sanz AJ, Basu A, Kovatchev B, Cobelli C, Doyle III FJ. 12 Week 24/7 Ambulatory Artificial Pancreas with Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia. Diabetes Care. 2017;40(12):1719-26. 4. Huyett LM, Ly TT, Forlenza GP, Reuschel-DiVirgilio S, Messer LH, Wadwa RP, Gondhalekar R, Doyle III FJ, Pi[INVESTIGATOR_45905], Maahs DM, Buckingham BA, Dassau E. Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. Diabetes Technol Ther. 2017;19(6):331-9. Epub 2017/05/02. doi: 10.1089/dia.2016.0399. PubMed PMID: 28459617; PMCID: PMC5510043. 5. Forlenza GP, Deshpande S, Ly TT, Howsmon DP, Cameron F, Baysal N, Mauritzen E, Marcal T, Towers L, Bequette BW, Huyett LM, Pi[INVESTIGATOR_45905], Gondhalekar R, Doyle III FJ, Maahs DM, Buckingham BA, Dassau E. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Diabetes Care. 2017. 6. Lee JB, Dassau E, Gondhalekar R, Seborg DE, Pi[INVESTIGATOR_45905], Doyle III FJ. Enhanced Model Predictive Control (eMPC) Strategy for Automated Glucose Control. Ind Eng Chem Res. 2016;55(46):[ZIP_CODE]-68. doi: 10.1021/acs.iecr.6b02718. 7. Laguna Sanz AJ, Doyle III FJ, Dassau E. An Enhanced Model Predictive Control for the Artificial Pancreas Using a Confidence Index Based on Residual Analysis of Past Predictions. J Diabetes Sci Technol. 2017;11(3):537-44. doi: doi:10.1177/1932296816680632. 8. Pi[INVESTIGATOR_45905], Laguna Sanz AJ, Lee JB, Church M, Andre C, Lindsey L, E,, Doyle III FJ, Dassau E. Evaluation of an Artificial Pancreas with Enhanced Model Predictive Control (eMPC) and a Glucose Prediction Trust Index with Unannounced Exercise. Diabetes Technol Ther. 2018;20(7):455-64. doi: 10.1089/dia.2018.0031. 
 
DCLP4 PROTOCOL V6.0 14DEC2020 PAGE 68 OF 68 9. Deshpande S, Pi[INVESTIGATOR_45905], Zavitsanou S, Shi D, Tompot R, Church MM, Andre C, Doyle III FJ, Dassau E. Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development. Diabetes Technol Ther. 2019;21(1):35-43. Epub 2018/12/15. doi: 10.1089/dia.2018.0278. PubMed PMID: 30547670; PMCID: PMC6350072. 